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The purpose of this Clinical Practice Guideline is to
provide guidance on evaluation of the kidney donor and trans-
plant recipient as well as on the management of the recipient
in the perioperative period. It is designed to provide infor-
mation and aid decision-making. It is not intended to deﬁne a
standard of care, and should neither be construed as one nor
should it be interpreted as prescribing an exclusive course of
management.
Scope and target population
This guideline describes the issues related to selection
and evaluation of the kidney donor and transplant recipient. It
encompasses aspects of immunological risk assessment and
management as well as perioperative care of the recipient.
It does not address prevention and treatment of complications
that occur after kidney transplantation, nor does it cover
immunosuppressive treatment at any stage. For these topics
we refer to the Kidney Disease Improving Global Outcomes
(KDIGO) guideline on kidney transplantation [1] and
the European Renal Best Practice Endorsement of this guide-
line [2].
Although many of the issues that are important for kidney
transplant candidates and their donors are also important for
potential recipients of other organs, we intend this guideline
for the setting of kidney transplantation only. When discuss-
ing aspects of screening for and mediation of risk factors in
the kidney transplant candidate, we only assess this in function
of the kidney transplant that is to follow. Although many of
these are relevant to other surgical procedures and to individ-
uals with chronic kidney disease not opting for kidney trans-
plantation, these aspects of care will not be addressed in this
document.
This guideline is targeted to all kidney transplant candi-
dates and their donors irrespective of age. Occasionally, when
applicable, only children are targeted, and then this is clearly
indicated.
Target population perspectives
An effort has been made to capture the perspectives of the
target population by adopting two strategies.
Firstly, European Renal Best Practice has a permanent
patient representative on its board. Although he was not in-
cluded in the guideline development group or in the evidence
review process, drafts of the guideline document were sent out
for his review and his comments were taken into account in re-
vising drafts of the ﬁnal document.
Secondly, the guideline was sent out for public review
before publication. All members of the European Renal
Association—European Dialysis Transplant Association
(ERA-EDTA) received an online questionnaire with a pre-
speciﬁed answer grid.
In this grid, on a scale from 1 to 5, ERA-EDTA members
could express to what extent they felt the individual statements
were clear, implementable and to what extent they agreed with
the content. In addition, a free text ﬁeld was provided to allow
for additional comments.
Target users
This guideline was written for health care professionals
dealing with kidney transplantation. This includes nurses,
general practitioners, transplant nephrologists, transplant sur-
geons and other physicians and medical professionals who di-
rectly or indirectly care for kidney transplant candidates and
their living donors. It is also directly targeted at kidney trans-
plant candidates and their living donors, to help them balance
beneﬁts and harms of various management strategies and
tailor management to their personal preferences and values.
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METHODS FOR GUIDELINE DEVELOPMENT
Establishment of the guideline development group
The ERBP Board members appointed the Chair and
Co-chair of the guideline development group, who then as-
sembled the guideline development group to be responsible
for the development of the guideline. The guideline de-
velopment group consisted of individuals with expertise in
transplant immunology, adult and paediatric nephrology,
transplant surgery and medicine. The European Renal Best
Practice (ERBP) Methods Support Team provided support in
guideline development and systematic review methodology.
The ERBP Methods Support Team is a group of young ne-
phrologists trained in guideline development and systematic
review methodology. Throughout the process they contributed
methodological input and assistance with literature searches—
together with methodology experts at the Cochrane Renal
Group in Sydney, Australia.
Deﬁning clinical questions
Speciﬁc clinical questions were developed within the guide-
line development group to reﬂect the key issues in the manage-
ment and evaluation of the kidney donor and recipient. They
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CHAPTER 1 . EVALUATION OF THE KIDNEY
TRANSPLANT CANDIDATE
(1) Should we actively screen for the presence of malig-
nancy in kidney transplant candidates? Is the presence
or history of malignancy a contraindication to kidney
transplantation?
(2) Under which conditions can HIV infected patients be
enrolled on the waiting list?
(3) Is there a role for immunization against herpes varicel-
la-zoster (HVZ) prior to kidney transplantation?
(4) Should Haemolytic Uraemic Syndrome (HUS) as
underlying cause of end-stage kidney disease preclude
waitlisting for transplantation and does it inﬂuence
graft and patient survival post-transplantation?
(5) Should focal segmental glomerulosclerosis (FSGS) as
underlying cause of end-stage kidney disease preclude
waitlisting for transplantation and does it inﬂuence
graft and patient survival post-transplantation?
(6) Does pre-transplant alcohol and drug abuse in patients
inﬂuence patient or graft survival?
(7) Does pre-transplant tobacco smoking in patients inﬂu-
ence patient or graft survival?
(8) Should obesity preclude waitlisting for kidney trans-
plantation and is there a difference in outcomes
post-transplantation between those with and without
obesity?
(9) Should kidney transplantation be delayed in patients pre-
senting with uncontrolled secondary hyperparathyroid-
ism? Does uncontrolled secondary hyperparathyroidism
in the immediate pre-transplant period have an impact
on transplant outcomes?
(10) How should screening for potential cardiovascular
disease in the potential recipient be done in a cost-effec-
tive way?
(11) When and for which indications should native ne-
phrectomy be performed in kidney transplant candi-
dates awaiting kidney transplantation?
CHAPTER 2 . IMMUNOLOGICAL WORK-UP
OF KIDNEY DONORS AND RECIPIENTS
(1) How should human leucocyte antigen (HLA) typing
be performed in kidney transplant candidates and
donors?
(2) In a kidney transplant recipient, how should HLA
matching be used to optimize outcome?
(3) In kidney transplant candidates, what HLA antigens and
non-HLA antigens should be deﬁned in addition to
HLA-A, -B and -DR?
(4) In HLA-sensitized kidney transplant candidates what
measures should be attempted to improve the probability
of a successful transplantation?
(5) Should in kidney transplant candidates a failed allograft
that still is in place be removed or left in place?
(6) In kidney transplant candidates, what technique of cross-
match should be used to optimize outcomes?
(7) In kidney transplant candidates planned to undergo
living donor transplantation but for whom the available
donor is ABO incompatible, what measures can be
undertaken to improve outcome after transplantation?
(8) In previously transplanted patients, what is the effect of
repeated mismatches for HLA antigens on outcomes, as
compared to avoiding repeated HLA mismatches?
CHAPTER 3 . EVALUATION, SELECTION
AND PREPARATION OF DECEASED AND
LIVING KIDNEY DONORS
(1) When is dual transplantation preferred over single trans-
plantation?
(2) Which perfusion solution is best suited for kidney pres-
ervation in recipients of living donation? Which per-
fusion solution is best suited for kidney preservation in
recipients of deceased kidney donation?
(3) Is machine perfusion superior to standard perfusion?
(4) Is there a critical cold ischaemic time beyond which a
donated organ should be discarded?
(5) On which criteria should we select living kidney donors
to optimize the risk–beneﬁt ratio of their donation?
(6) What lower limit of kidney function precludes living
donation?
(7) What are the risks of pregnancy in a woman with a
single kidney after living donation?
(8) What is the best surgical approach for living donor ne-
phrectomy for the donor? What is the best surgical ap-
proach for living donor nephrectomy for the recipient?
CHAPTER 4 . PERIOPERATIVE CARE OF THE
KIDNEY TRANSPLANT RECIPIENT
(1) What are the indications for additional haemodialysis
in the recipient immediately before the transplantation
procedure?
(2) Does the use of central venous pressure measurement as
a guidance tool for ﬂuid management in kidney trans-
plant recipients improve the outcome after transplan-
tation?
(3) In kidney transplant recipients during the perioperative
period, does the use of intravenous solutions other than
0.9% sodium chloride improve patient and/or graft
outcome?
(4) Does the use of dopaminergic agents (dopamine and its
alternatives) improve early post-operative graft function?
(5) Should we use prophylactic antithrombotic agents
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(6) In kidney transplant recipients, what are the effects of
using a JJ stent at the time of operation on outcomes?
(7) What is the optimal post-operative time for removal of
the indwelling bladder catheter in kidney transplant reci-
pients?
The Methods Support Team assisted the guideline develop-
ment group in framing the clinical questions into a PICO
format, a well-accepted methodology which requires break-
down of the clinical question with careful speciﬁcation of a
patient group, the intervention diagnostic test or risk factor,
the comparator and the outcomes or target disease of interest
[3]. For each question the guideline development group and
Methods Support Team agreed upon explicit criteria for the
patient group, intervention or risk factor, comparators, out-
comes and study design features (Appendix 1).
Assessment of the relative importance of the outcomes
For each question, the guideline development group com-
piled a list of outcomes, reﬂecting both beneﬁts and harms of
alternative management strategies. The guideline development
group ranked the outcomes as critical, highly or moderately
important according to their relative importance in the
decision-making process. As such, outcomes such as patient
and graft survival were considered critical. Outcomes such as
acute rejection and graft function were considered highly
important, and surrogate outcomes such as blood pressure
were considered moderately important outcomes (Table 1).
Searching for evidence
Sources. The Methods Support Team initially searched The
Cochrane Database of Systematic Reviews, DARE, CENTRAL
and MEDLINE (from 1948) in May 2010. All searches were
updated in July 2011 and supplemented by articles identiﬁed
by the guideline development group members through Febru-
ary 2012. The search strategies combined subject headings and
text words for the patient group, and the intervention or risk
factor under assessment. The full search strategies are detailed
in Appendix 2. We also searched guideline databases and
organizations including the National Guideline Clearinghouse,
Guidelines International Network, Guidelines Finder, Centre
for Reviews and Dissemination, National Institute for Clinical
Excellence and professional societies of Nephrology and
Transplantation to screen the reference lists. Searching was re-
stricted to electronically available information. We did not
attempt hand-searching, nor searching grey literature.
Searching hierarchy and selection criteria. For questions
on treatment, we adopted a hierarchical search strategy in
which we ﬁrst tried to identify eligible systematic reviews of
randomized controlled trials. If not available, of insufﬁcient
quality or if they did not fully address the question, we
searched for individual eligible randomized controlled trials. If
the systematic reviews were of sufﬁcient quality but outdated,
we restricted our search to the time period since the end of the
literature search within the systematic reviews. If randomized
controlled trials were not available, underpowered, at moderate
to high risk of bias or if they did not fully address the question,
we tried to identify all relevant observational data. For prog-
nostic questions, we tried to identify all relevant observational
data irrespective of sample size.
We included all studies conducted in humans without re-
strictions based on language. Inclusion and exclusion criteria
for each question were deﬁned within the PICO-framed ques-
tions (Appendix 1). Citations were screened on title and ab-
stract by a member of the Methods Support Team to discard
clearly irrelevant ones. A second screening was done a
member of the guideline development group. All abstracts that
did not meet the inclusion criteria were discarded. Any discre-
pancies at this stage were resolved by consensus.
Assisted by the Cochrane Renal Group’s Information
Specialist, the Methods Support Team retrieved full texts for
potentially relevant studies. The guideline development group
members then examined them for eligibility according to the
predeﬁned eligibility criteria.
Data extraction and critical appraisal of the literature
For each included study, relevant information on design
and conduct and relevant results were collected through a
standardized data extraction sheet in Microsoft Excel (2010).
Data were extracted by the guideline development group
members and further checked by a member of the Methods
Support Team. Discrepancies were resolved by consensus.
A template is available from Appendix 3. The full tables are
available online from Appendix 4.
Risk of bias of the included studies was evaluated using
validated checklists, as recommended by the Cochrane Collab-
oration. These are AMSTAR for Systematic reviews [4], the
Cochrane Risk of Bias tool for randomized controlled trials [5]
and the Newcastle Ottawa scale for Cohort and Case–control
studies [6]. As such, the risk of bias was assessed by study and
across outcomes. We deﬁned three categories for the overall
assessment of the risk of bias at study level: ‘high’, ‘moderate’
and ‘low’, reﬂecting the extent to which the guideline
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development group members were conﬁdent that the effect
sizes in the study were close to that of the true effect.
Formulating and grading recommendations: GRADE
After the data tables were prepared, revised and approved
by the guideline development group three full-day plenary
meetings were held in December 2011, February 2012 and
May 2012 to formulate and grade the recommendations. We
used a structured approach, based on Grading of Recommen-
dations Assessment, Development and Evaluation Working
Group (GRADE) methodology to grade the quality of the evi-
dence and the strength of the recommendations [7]. GRADE
offers a system for separately rating the quality of the evidence
and grading the strength of the recommendations in the
guideline. The ‘strength’ of a recommendation indicates the
extent to which we are conﬁdent that adherence to the rec-
ommendation will do more good than harm. The ‘quality’ of
the evidence refers to the extent to which we are conﬁdent that
the estimates of effect across studies are close to the true
effects (Figure 1).
Rating the quality of the evidence for each outcome. In
accordance with GRADE, we—guideline development group
together with the Methods Support Team—initially categor-
ized the quality of the evidence for each outcome as high if it
originated predominantly from randomized controlled trials
and low if it originated from observational data. We sub-
sequently downgraded the quality of the evidence one level if
the results from individual studies were at serious risk of bias;
there were serious inconsistencies in the results across studies;
the evidence was indirect; the data were sparse or imprecise;
and publication bias was thought to be likely. If evidence arose
from observational data, but effect sizes were large, or there
was evidence of a dose–response gradient, or all plausible con-
founding would either reduce a demonstrated effect or suggest
a spurious effect when results showed no effect, we would
upgrade the quality of the evidence. The ﬁnal grade for the
quality of the evidence for each intervention or risk and
outcome pair would eventually be one of high, moderate, low
or very low (Table 2).
Rating overall quality of the evidence. Each clinical
outcome was ranked by the guideline development group ac-
cording to its relative importance to the patient. The overall
body of evidence was then graded, taking into account the
quality of the evidence for each outcome and judgement about
the relative importance of each outcome. This resulted in four
aggregated categories A, B, C or D (Figure 1 and Table 3).
Grading the strength of the recommendation. Recommen-
dations can be for or against a certain strategy. Following
GRADE, we classiﬁed the strength of the recommendations as
strong, coded ‘1’ or weak, coded ‘2’ [7]. Table 4 shows the
implications of strong and weak recommendations for
patients, clinicians and policy-makers.
Judgements around four key factors determined the
strength of a recommendation: the balance between desirable
and undesirable consequences of alternative management
strategies, the quality of the evidence, the variability in values
and preferences and ultimately also resource use. We did not
conduct formal decision or cost analyses.
Ungraded statements
We decided to use an additional category of ‘ungraded
statement’ for areas where formal evidence was not available
and statements were based on common sense, or expert
experience alone. They were termed ‘statement’ to differentiate
them from graded recommendations and not meant to be
stronger than level 1 or 2 recommendations.
Writing rationale
Rationales were written by the guideline development
group members according to a pre-speciﬁed format. Each
question contains one or more speciﬁc boxed statements.
Within each recommendation the strength is indicated as level
1 or level 2 and the quality of the supporting evidence as A, B,
C or D. Ungraded statements are referred to as such, and do
not hold an indicator for the quality of the evidence. These are
followed by the rationale, which contains a brief section on
‘why this question’ with relevant background and rationale to
justify the topic, followed by a short narrative review of the evi-
dence in ‘what did we ﬁnd’ and ﬁnally a justiﬁcation of how
the evidence translated in the recommendations made in ‘how
did we translate the evidence into the statement’.
For each question we provided a narrative summary of the
relevant recommendations made by a selection of guideline
producing organizations issuing recommendations in the area
of kidney transplantation in Europe and beyond. It was not
meant to be an exhaustive list, but predominantly aimed to
represent major bodies in Europe and active ones beyond
(Table 5).
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Table 2. Method of rating the quality of the evidence
Step 1: starting grade according
to study design
Step 2: lower if Step 3: higher if Step 4: determine
ﬁnal grade for quality
of evidence
Randomized trials = High


















+ 2 Very large
Dose response
+ 1 Evidence of a gradient
All plausible confounding
+ 1 Would reduce a demonstrated effect
+ 1 Would suggest a spurious effect










A High We are conﬁdent that the true effects lies close to that of the estimates of the effect
B Moderate The true effects are likely to be close to the estimates of the effects, but there is a possibility that
they are substantially different
C Low The true effects might be substantially different from the estimates of effects
D Very low The estimates are very uncertain, and often will be far from the truth
Table 4. Implications of strong and weak recommendations for stakeholders
Implications
Grade Patients Clinicians Policy
1—strong
‘We recommend’
Most people in your situation
would want the recommended
course of action, only a small
proportion would not
Most patients should receive the
recommended course of action
The recommendation can be




Most people in your situation
would want the recommended
course of action, but many
would not
You should recognize that
different choices will be
appropriate for different
patients
You must help each patient to
arrive at a management decision
consistent with her or his values
and preferences














 at Bibliotheque Fac de M






Finally, we attempted to provide relevant suggestions for
future research where possible.
ORGANIZATION OF INTERNAL AND
EXTERNAL REVIEW
Internal review
A ﬁrst draft of the guideline was sent to experts in trans-
plantation, selected by the chair and co-chair. (in alphabetical
order):
• Klinger Marian, Department and Clinic of Nephrology and
Transplant Medicine, Medical University of Wrocalw,
Poland
• Krämer Bernhard, Universitätsklinikum Mannheim,
Germany
• Martorell Julio, Servicio de Immunologia, Hospital de
Clinic de Barcelona, Spain
• Roodnat Joke, Erasmus Medical Center Rotterdam, Rotter-
dam, the Netherlands
• Watschinger Bruno, Universitätsklinik für Innere Medizin,
Nephrologie und Dialyse, Wien, Austria
• Wiseman Alexander, Division of Renal Diseases and
Hypertension, University of Colorado, Denver, USA
Internal reviewers were asked to complete a grid-based
evaluation of overall appreciation of each individual state-
ment, using a score ranging from 1 to 5. These scores
were averaged and colour-coded between red (1) and
green (5) to help visualize any problematic part. In
addition, internal reviewers were asked to comment on
the statements and the rationale within free text-ﬁelds
limited to 225 characters. All these comments and sugges-
tions were discussed during an additional meeting of the
guideline development group in October 2012. For each
comment or suggestion, the guideline development group
evaluated whether it was needed to adapt the statement,
again taking into account the balance between desirable
and undesirable consequences of the alternative manage-
ment strategies, the quality of the evidence, the variability
in values and preferences and ultimately also resource use.
External review
The ﬁnalized version of the guideline was sent to the
European Society of Transplantation, with the invitation
to select three reviewers from their membership. C.C.
Baan, C. Legendre and F. Diekmann were indicated and
reviewed the guideline. External reviewers were asked to
complete a grid-based evaluation of overall appreciation of
each individual statement, using a score ranging from 1 to
5. These scores were averaged and colour-coded between
red (1) and green (5) to help visualize any problematic
part. In addition, external reviewers were asked to
comment on the statements and the rationale within free
text-ﬁelds limited to 225 characters.
The same evaluation grid, but without potential to write
free text comments, was also made publicly available to the
ERA-EDTA membership and the members of Descartes
working group. In total, 648 ERA-EDTA members and 27
Descartes members responded.
All these valid comments and suggestions were discussed
with the subgroups by e-mail, and during a ﬁnal meeting of
the chair of the guideline development group (Daniel Abra-
mowicz) and the chair of ERBP (Wim Van Biesen). As a
result, one ungraded statement, that was considered to be in-
appropriate by the external reviewers, was removed.
Timeline and procedure for updating the guideline
ERBP plans to update the guideline every 5 years, or
when new evidence emerges that might require changes to
individual statements. At least every 5 years, they will
update its literature searches. Relevant papers will be
identiﬁed and their data will be extracted using the same
procedure as for the initial guideline. The guideline devel-
opment group will then decide whether or not the original
statement needs to be updated. The guideline will then be
published as a whole online in the revised version, and a
position statement describing the changes will be pub-
lished with an accompanying rationale in Nephrology,
Dialysis and Transplantation.
During the 5-year interval, designated members of the ad-
visory board (‘watchdogs’) will follow the literature, and signal
the chair and co-chair of the guideline development group
when new information is published that might require
changes to speciﬁc statements. The chair and co-chairs of the
guideline development group will then decide whether an
update is needed. If they deem an update is warranted, data
from the additional paper will be extracted and added to
the original data extraction table. A position statement will be
produced and published in Nephrology, Dialysis and
Transplantation.
Table 5. Selected guideline producing
organizations
Kidney Disease: Improving Global Outcomes (KDIGO)
Canadian Society of Nephrology (CSN)
Kidney Health Australia – Caring for Australasians with
Renal Impairment (KHA-CARI)
The Renal Association (UK)
European Association of Urology (EAU)
British Transplant Society (BTS)
Société Francophone de Néphrologie
Deutsche Gesellschaft für Nephrologie
Società Italiana di Nefrologia
Sociedad Espagnola de Nefrologia
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This guideline was produced on the budget of ERBP, the
guideline producing body of ERA-EDTA. Activities of ERBP
are supervised by an advisory board (see www.european-renal-
best-practice.org for details and declaration of interests).
ERBP is an independent part of ERA-EDTA, and is funded by
an unrestricted grant by ERA-EDTA. The amount of this yearly
grant is based on a budget that is proposed on a yearly basis by
the chair of ERBP to the ERA-EDTA council for approval.
All these secure ERBP can act independently from industry
and other possible inﬂuences.
CONFLICT OF INTEREST POLICY
We required all participants in the guideline development
group to ﬁll out a detailed Declaration of Interest State-
ment. We did not however attach any consequences to
these stated interests. All members of the guideline devel-
opment group were allowed to participate in all the
discussions and have equal weight in formulating the
statements. All were allowed equal involvement in data
extraction and writing the rationales. The declaration of
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CHAPTER 1 . EVALUATION OF THE KIDNEY
TRANSPLANT CANDIDATE
1.1. Should we actively screen for presence of malignancy in
kidney transplant candidates? Is presence or history of
malignancy a contraindication to kidney transplantation?
We recommend screening kidney transplant candidates
for cancer according to the recommendations that apply to
the general population. (Ungraded Statement)
We suggest screening kidney transplant candidates for
the presence of kidney cancer by ultrasound. (Ungraded
Statement)
We suggest screening for the presence of urothelial
cancer by urinary cytology and cystoscopy in kidney trans-
plant candidates with an underlying kidney disease associ-
ated with an increased risk of this type of cancer.
(Ungraded Statement)
We recommend screening HCV and HBV-infected
kidney transplant candidates for the presence of hepatocel-
lular carcinoma according to the EASL-EORTC Clinical
Practice Guideline on the management of hepatocellular
carcinoma. (Ungraded Statement)
We suggest that patients with current or previous cancer
be discussed with an oncologist and considered on a case-
by-case basis. The following factors should be considered
when determining the appropriate time that wait-listing
should be delayed: (a) the potential for progression or re-
currence of the cancer according to its type, staging and
grade; (b) the age of the patient; (c) the existence of co-
morbidities, in order to deﬁne the appropriate period




Kidney transplantation is associated with an increased risk of
cancer. Screening in transplant candidates is aimed at avoiding
kidney transplantation, and its associated immune suppression
in a patient with an unknown cancer present. To optimize sur-
vival of the recipient and of the graft, optimized screening pro-
tocols are needed. In transplant candidates diagnosed with
cancer, the balance between mortality risk after transplantation
and remaining on dialysis should be deﬁned to guide optimal
timing of active wait-listing.
What did we ﬁnd?
Kidney transplant recipients are approximately three times
more likely to develop cancer than the general population
[9–14]. Estimates result mostly from large registry analyses
showing standardized incidence rates up to 10 times those
seen in the general population, depending on the type of
cancer [9–11, 13–23]. Most of these studies included patients
without specifying whether the presence of cancer had been
excluded before transplantation. Hence, it is unclear whether
this higher cancer risk was due to the presence of an undiag-
nosed cancer, to a true increased risk of developing cancer
after transplantation, or a combination of both.
We found no data evaluating the effectiveness of screening
protocols in transplant candidates; hence recommendations
are made based on extrapolations from the general population
taking into account the additional baseline risk of patients
with end-stage kidney disease.
Data on the recurrence of pre-existing cancers after kidney
transplantation come from two registry analyses with incon-
sistent results [24, 25]. Historical data gathered in the 1970s,
1980s and early 1990s showed that patients with previous
cancer experienced recurrence at an overall rate of 21% [26].
In the majority in whom the cancer recurred, it did so within
the ﬁrst 5 years after transplantation. Analysis for the Austra-
lian and New Zealand Transplant Registry found much lower
rates of cancer recurrence, ∼2–5% [25]. Plausible differences
in patient selection and cancer ascertainment make inference
problematic. As information on tumour staging in both regis-
tries is lacking, any attempt at risk estimation remains crude.
No data allowing more precise estimation of risk of recurrence
are available at this point.
How did we translate the evidence into the statement?
Diagnosis of cancer at earlier stages, changes in treatment, and
availability of new immunosuppressive agents urge us to re-
evaluate risk and prognosis of cancer in transplant candidates.
Unfortunately accurate evidence in this ﬁeld is lacking. The
guideline development group judged that, in view of the in-
creased prevalence and severity of cancer in both patients with
end-stage kidney disease and those after transplantation,
screening should be recommended. In the absence of validated
screening protocols for this speciﬁc patient group, we advocate
the screening recommendations that apply to the general
population as a minimal work-up.
Recommendations on how long patients should be withheld
from transplantation when a cancer is detected are trouble-
some. Given the important limitations of the existing registry
data, and the changes in medical practice and perhaps prog-
nosis over time, the guideline development group felt that
stringent generic recommendations according to the type of
tumour were no longer possible. A more reasonable,
although arguably a more difﬁcult approach is a case-per-
case analysis, taking into account the potential for pro-
gression or recurrence of the cancer according to its type, but
also its staging, the age of the patient and potential comor-
bidities. Information to guide this discussion can be found
on the website of Adjuvent! online: adjuvantonline.com, or
on the website of the Laboratory for Quantitative Medicine of
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Based on consensus of personal opinion, the guideline de-
velopment group supported following suggestions:
We suggest that patients with in situ cancers of the skin and
uterine cervix, and patients with incidentally discovered and
successfully removed kidney cancer, can be immediately regis-
tered on the waiting list.
We suggest that patients with localized cancer of good progno-
sis such as cancers of the thyroid, uterus body, uterine cervix
or larynx wait 1–3 years before transplantation.
We suggest that patients with a potentially curable cancer such
as localized, or curable metastatic or disseminated cancer such
as testicular malignancy or lymphoma wait at least 1–3 years
before transplantation.
We suggest strongly discouraging transplantation for at least 5
years for cancers with a generally poor prognosis such as lung,
stomach, brain and oesophagus cancers, melanoma and me-
sothelioma.
We suggest strongly discouraging transplantation in patients
with metastatic or disseminated forms of any cancer, except
for testicular cancer and lymphomas.
What do the other guidelines state?
The UK Renal Association recommends a general waiting
time between successful tumour treatment/remission and
transplantation of at least 2 years and for certain malignancies
at least 5 years, referring mainly to the Penn database [24].
KHA-CARI agrees on screening in accordance to the general
population but does not speciﬁcally recommend screening for
renal, urothelial and hepatocellular cancer. KHA-CARI pro-
vides speciﬁc waiting times depending on the type of malig-
nancy, whereas we recommend an individual case-by-case
approach [27, 28]. The European Association of Urology en-
dorses similar recommendations to ERBP concerning that the
waiting time until transplantation depends on individual
patient and cancer-related facts [29].
Suggestions for future research
Development of prospective registry studies of all trans-
plant candidates reporting detailed information on pre-trans-
plant cancer diagnosis, screening results, acceptance on the
waiting list, recurrence and outcome.
Development and rigorous evaluation of screening proto-
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1.2. Under which conditions can HIV infected patients be
enrolled on the waiting list?
We recommend that HIV per se is not a contraindica-
tion for kidney transplantation. (1C)
We recommend waitlisting HIV patients only if
(1) they are compliant with treatment, particularly
HAART therapy
(2) their CD4+ T cell counts are >200/µL and have been
stable during the previous 3 months
(3) HIV RNA was undetectable during the previous
3 months
(4) no opportunistic infections occurred during the pre-
vious 6 months
(5) they show no signs compatible with progressive
multifocal leukoencephalopathy, chronic intestinal cryp-
tosporidiosis or lymphoma. (1C)
We suggest that the most appropriate anti-retroviral
therapy should be discussed before transplantation with
the infectious diseases team in order to anticipate potential




Around 1% of patients with chronic kidney disease stage 5D in
Europe and the USA are infected with human immunodeﬁ-
ciency virus (HIV) [30]. Since highly active antiretroviral
therapy (HAART) became widely available in 1996, the prog-
nosis of HIV infection has dramatically improved. Once con-
traindicated because of poor prognosis after kidney
transplantation [31], many transplant programmes are now
routinely transplanting HIV-infected candidates, provided
HIV infection is well controlled.
What did we ﬁnd?
Data on >500 carefully selected HIV-infected patients show
that patient and graft survival is similar to non-HIV patients
up to 3–5 years after transplantation [32–44]. However, most
of these studies applied stringent inclusion and exclusion cri-
teria:
CD4 >200 cells/µL for at least 3 months; undetectable HIV vir-
aemia (<50 copies/mL) for at least 3 months; demonstrable ad-
herence overall and with HAART therapy in particular;
absence of AIDS-deﬁning illness following successful immune
reconstitution after HAART.
The use of immunosuppressive agents does not seem
to destabilize HIV control, with patients showing stable
CD4+ levels, anecdotal occurrence of viral replication and op-
portunistic infections. Data on acute rejection rates are higher
—up to 2- to 3-fold—in some [38, 40, 41], but not all reports
[34, 35, 39, 42].
How did we translate the evidence into the statement?
Based on the currently available data, the guideline develop-
ment group judged that patients should not be denied waitlist-
ing for transplantation based on the presence of HIV infection
alone. As so far, the positive results have been observed in
highly selected patients, the guideline development group
judged that the following criteria should be met: patients are
compliant overall and with HAART therapy in particular,
CD4+ T cell levels are >200/µL and have been stable during
the last 3 months, HIV RNA was undetectable during the last
3 months, no opportunistic infections occurred during the last
6 months, no signs are present compatible with progressive
multifocal leukoencephalopathy, chronic intestinal cryptos-
poridiosis or lymphoma.
The reported higher rejection rate in some studies can poten-
tially be attributed to the difﬁculty to obtain a good balance
between immunosuppression and controlled viral replication.
Achieving this balance is further hampered by the potent drug
interactions between anti-retroviral and immunosuppressive
drugs, e.g. protease inhibitors that potently impair cytochrome
P-450 enzyme function leading to calcineurin inhibitor intoxi-
cation. For all these reasons, the guideline development group
judged that the most appropriate anti-retroviral therapy for an
individual patient should be discussed with the infectious dis-
eases team before transplantation. The use of antiretrovirals
such as integrase inhibitors that do not inhibit the cytochrome
P-450 enzyme system may simplify the use of immuno-
suppressants in this setting and decrease the frequency of re-
jection [43].
What do the other guidelines state?
KHA-CARI endorses similar recommendations, but
demand a CD4+ T cell count >200/µL for 6 months and do
not specify a certain time period free of opportunistic infec-
tions prior to transplantation [45].
Suggestions for future research
Evaluation of effectiveness, safety, pharmacokinetic
proﬁles and drug–drug interactions of new anti-HIV medi-
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1.3. Is there a role for immunization against herpes varicel-
la-zoster prior to kidney transplantation?
We recommend immunization against varicella-zoster
virus in all paediatric and adult patients negative for anti-




Varicella may be a severe and even fatal disease in the immu-
nocompromised child and adult. Vaccination is available but
not routine in the general population in most countries.
What did we ﬁnd?
Almost 50% of paediatric patients on the waiting list for
kidney transplantation are seronegative for antibodies against
varicella-zoster virus (VZV) [46]. Three to ten per cent of
adult kidney transplant candidates are negative for anti-VZV
antibodies [47, 48]. After a single dose of vaccine, 50–82%
develop a protective antibody titre [46, 48, 49]. After two
doses, separated by 3 to 4 months, 73–94% do so [46, 48–50].
Protective titres may be lost with time and a third dose may be
necessary [51]. In chronic kidney failure, the vaccine appears
more effective in children younger versus older than 6 years of
age [46]. Vaccination before transplantation seems to be well
tolerated with mild varicella and ﬂu-like symptoms being the
only reactions seen. In transplanted children with versus
without varicella vaccination, varicella infection incidence is
lower (12 versus 45%, P < 0.001), as is the severity of the illness
(P < 0.04). Also reactivation (Herpes Zoster) is lower
(11 versus 38%, P < 0.001) [51]. All these data stem from ob-
servational studies uncontrolled for potential confounding
such as time effect. A pre-transplant vaccination programme
against varicella is reported as cost-effective when
compared to treatment with varicella-zoster immunoglobulin
[52, 53].
How did we translate the evidence into the statement?
Although studies are largely limited by their observational
character and univariate analyses, data seem to suggest pro-
tective titres are easily achieved after two doses with reduced
incidence of both varicella-zoster infection and reactivation.
Additionally, reported side-effects appear to be infrequent
and benign. The cost of a pre-transplant vaccination pro-
gramme is relatively low. Taking all this into account, the
guideline development group felt that the risk–beneﬁt
balance is in favour of vaccinating all sero-negative children
and by extrapolation all seronegative adults awaiting kidney
transplantation.
What do the other guidelines state?
These recommendations correspond with those of KDIGO
[1], UK Renal Association [28] and KHA-CARI [54].
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1.4. Should haemolytic uraemic syndrome (HUS) as under-
lying cause of end-stage kidney disease preclude waitlisting
for transplantation and does it inﬂuence graft and patient
survival post-transplantation?
We recommend that typical, proven shiga-toxin Escheri-
chia coli-associated HUS is not a contraindication to trans-
plantation from either deceased or living donors. (1B)
We suggest considering kidney transplantation as an ac-
ceptable option (i) in kidney transplant candidates with
atypical HUS (aHUS) and a proven membrane cofactor
protein (MCP) mutation and (ii) in those displaying anti-
complement factor H (CFH) auto-antibodies. (Ungraded
Statement)
We suggest that kidney transplantation in patients
with aHUS should only be undertaken in centres with
experience in managing this condition and where appro-
priate therapeutic interventions are available. (Ungraded
Statement)
We do not recommend living donation from a geneti-
cally related donor in patients who are suspected to have
aHUS as their underlying kidney disease unless the respon-
sible mutation has been conclusively excluded in the
donor. (1D)
We recommend evaluating the potential of living
donation from a genetically unrelated donor to a recipient
with aHUS on a case-by-case basis. It should only be con-
sidered after appropriate counselling of recipient and




The HUS is a condition that can recur after transplantation.
Recently, HUS has been associated with several distinct ab-
normalities in complement genes, a condition named aHUS.
The insights in the underlying pathophysiology of the different
forms of aHUS are rapidly evolving, and accordingly so is the
evaluation of the risk of recurrence after transplantation.
What did we ﬁnd?
Most cases of HUS, including >90% of those in children, are
secondary to infection with E. coli serotypes O157:H7 and
others, which produce Shiga-like toxin [55].
We found three studies retrospectively reviewing outcomes after
transplantation in Shiga-like toxin-associated HUS. All found
recurrence rates to be extremely low (0–1%) [55–57]. It has
been hypothesized that in the cases in which HUS did recur, the
condition was in fact associated with unrecognized genetic
mutations, but this has not been directly proven.
aHUS presents as either a familial (<20%) or a sporadic form
(>80%) [58]. Both autosomal dominant and recessive patterns
of inheritance have been reported. About two-thirds of
familial forms have been linked to distinct complement ab-
normalities—mutations in CFH 40–45%; in complement
factor I (CFI) 5–10%; in C3, 8–10%; in MCP 7–15%; in throm-
bomodulin (THBD) 9% and in complement factor B (CFB) 1–
2% [58] . The genetic abnormalities identiﬁed in the sporadic
(mainly idiopathic) form of the disease are those that have also
been documented in the familial form of aHUS. Of note, at
least 10% of affected patients have a combination of two
mutations. In addition to mutations, various polymorphisms
in genes encoding complement proteins may have some con-
tribution to the degree of susceptibility to HUS. Finally, anti-
bodies to CFH have been found in 6–10% of patients affected
by sporadic aHUS.
Altogether, aHUS is reported to recur in ∼50–60% of patients
who undergo transplantation, and graft failure occurs in 80–
90% of those with recurrent disease [58–61]. Importantly, re-
ported post-transplant recurrence rate varies depending on the
particular genetic abnormality with 70–90% in CFH and CFI
mutations and <20% in patients with MCP mutations.
How did we translate the evidence into the statement?
Research has linked aHUS to uncontrolled activation of the
alternative complement pathway. Kidney transplantation may
trigger aHUS recurrence because of cold ischaemia that
induces graft-derived C3 production, endothelial injury due to
calcineurin inhibitors, anti-HLA antibodies and infections.
It is sometimes advised that patients should undergo a
thorough screening before transplantation for blood levels of
C3, CFH, CFI, CFB, the presence of anti-CFH auto-antibodies
and membrane CP expression on peripheral blood leucocytes,
and be genotyped for mutations in CFH, MCP, CFI, C3, CFB,
THBD as well as for CFH-related deletions.
The ERBP guideline development group judged that, while ob-
taining such a complete work-up would be ideal for research
purposes, at present it is expensive, logistically difﬁcult to
organize, and may take several months, while the clinical rel-
evance of this information is very low. We believe currently
only the presence of an MCP mutation or anti-CFH antibodies
is clinically relevant for the discussion of the option of trans-
plantation with the patient. Indeed, MCP-associated aHUS
recurs in only 20% of cases, and recurrence due to anti-CFH
antibodies is potentially manageable. Still then, it should not
be neglected that some patients have more than one mutation.
In case of aHUS based on a MCP mutation, living donation
from a genetically related donor should only be considered
after careful exclusion of aHUS-associated mutations in the
donor, not only for MCP, but also all other known mutations.
In any case, we suggest that kidney transplantation should
only be undertaken if appropriate therapeutic measures are
available post-transplantation. Different therapeutic options
[eculizimab, plasma exchange] are currently being explored.
Data to support any of these strategies are lacking so far
however, and are eagerly awaited.
Living-donor transplantation is contraindicated in patients
with aHUS because of the high risk of recurrence. In addition,
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may carry an unrecognized genetic susceptibility factor or be
mutations carriers and develop ‘de novo’ aHUS.
What do the other guidelines state?
The British Transplant Society suggests similarly to ERBP
that living-related kidney transplantation is not recommended in
aHUS [62]. While ERBP suggests that kidney transplantation is
an acceptable option in candidates with a provenMCPmutation,
the British Transplant Society suggests informing these patients
who the risk of recurrence after kidney transplantation is low.
The British Transplant Society does not recommend
kidney transplantation in candidates with a factor H or I
mutation; it recommends that if either isolated liver or com-
bined liver/kidney transplantation are considered, this should
only be done as part of an international clinical trial.
The British Transplant Society suggests informing patients
with mutations in C3 and CFB of their high risk of recurrence
after transplantation and recommends minimizing antibody
titres in patients with anti-factor H autoantibodies before
transplantation, whereas ERBP does not provide guidance on
these speciﬁc mutations.
Suggestions for future research
Registries of aHUS patients could reﬁne the association
between genotype–phenotype and outcome of transplantation.
Trials investigating the efﬁcacy of eculizumab in the pre-
vention and treatment of post-transplant aHUS recurrences in
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1.5. Should focal segmental glomerulosclerosis (FSGS) as
underlying cause of end-stage kidney disease preclude wait-
listing for transplantation and does it inﬂuence graft and
patient survival post-transplantation?
We recommend that primary focal segmental glomerulo-
sclerosis per se is not a contraindication to kidney trans-
plantation from either a living or a deceased donor. (1D)
We recommend informing the recipient and in living
donation, the potential donor, about the risk of recurrence
of focal segmental glomerulosclerosis in the graft.
(Ungraded Statement)
We recommend that when a ﬁrst graft has been lost
from recurrent focal segmental glomerulosclerosis, a
second graft from either a deceased or a living donor
should only be transplanted after an individual risk–beneﬁt
assessment and careful counselling of the recipient and
potential donor in the case of living donation. (Ungraded
Statement)
We suggest using an updated management protocol
in cases of recurrent focal segmental glomerulosclerosis.
(Ungraded Statement)
We suggest that children with steroid-resistant nephrotic
syndrome undergo appropriate genotyping before wait listing
them for kidney transplantation. (Ungraded Statement)
Rationale
Why this question?
FSGS accounts for ±10% of childhood end-stage kidney disease
and, depending on age, 1–5% of adult end-stage kidney disease.
Primary FSGS may recur after transplantation and lead to rapid
graft loss. As this disease typically occurs in younger patients, it
is quite likely that the possibility of living donation will be con-
sidered by the patient or his/her family. In the same context, it
should be considered that a second transplantation might be
needed during the course of the patient’s life.
What did we ﬁnd?
Secondary FSGS classically does not recur after kidney trans-
plantation. The reported recurrence rate of primary FSGS
however lies between 34 and 56% [63–68].
Graft loss occurs in ± 30–50% of patients with FSGS recur-
rence after transplantation, resulting in an overall graft loss
due to FSGS recurrence of ±10–15% [63, 65, 68, 69]. The re-
ported risk of relapse is high (±80–100%) in those with a
history of allograft loss due to recurrent FSGS [65, 68, 70].
FSGS patients with mutations of the NPHS1 and NPHS2
genes, only rarely experience recurrence after transplantation
[65, 67, 71]. Therapy of recurrent disease with high-dose cy-
closporine, steroids and PE has been associated with partial or
complete remission in 17/42 patients [64].
How did we translate the evidence into the statement?
Recurrence of primary FSGS after ﬁrst transplantation is
rather high, but leads to graft loss in only 10–15% of cases. In
view of the potential advantages of transplantation over re-
maining on dialysis, the guideline development group judged
that under these conditions there is sufﬁciently positive risk–
beneﬁt to not preclude the option of transplantation.
However, the increased risk of recurrence with its associated
substantial morbidity and potential need for aggressive inter-
ventions need to be clearly communicated to the patient and
his next of kin. Potential living donors should be informed
about the risk of recurrence and graft loss.
Treating recurrent disease after transplantation can be chal-
lenging. Aggressive treatment protocols with high-dose plas-
mapheresis, cyclosporine and steroids have been advocated
with some success in small series. To the opinion of the
guideline development group the transplant team
should therefore have a well-deﬁned updated management
strategy to both detect and treat focal segmental glomerulo-
sclerosis recurrence in order to optimize prognosis by early
intervention.
In view of the very high reported recurrence rate for a
second transplantation after recurrence in the ﬁrst graft, the
guideline development group judged that regrafting should be
strongly discouraged.
What do the other guidelines state?
No other guideline body has a statement on this topic.
Suggestions for future research
Randomized controlled trials evaluating effectiveness and
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1.6. Does pre-transplant alcohol and drug abuse in patients
inﬂuence patient or graft survival?
We recommend that women who drink >40 g and men
who drink >60 g of alcohol per day stop or reduce their
alcohol consumption to below these levels. (1D)
These patients can be waitlisted, but a careful surveil-
lance of reduction of alcohol consumption should be
exerted. (Ungraded Statement)
We recommend not waitlisting patients with alcohol
‘dependence’. (Ungraded Statement)
Strategies to stop alcohol consumption should be offered,
according to the World Health Organization (WHO) Clini-
cal Practice Guideline. (Ungraded Statement)
We recommend not waitlisting patients with an on-




Alcohol consumption is widely accepted and frequent in the
general population. Its use puts patients potentially at risk for
additional complications after transplantation. Especially ad-
herence, pharmacokinetic interactions and physical and psy-
chosocial consequences are of concern.
Transplantation in patients with drug abuse poses challenging
clinical and ethical questions, both for the personal outcome
of the individual as for the fair allocation of organs.
What did we ﬁnd?
Various categories of alcohol consumption have been
deﬁned and interchangeably used in the literature. The
WHO deﬁnes three categories: hazardous alcohol drinking
(20–40 g/day for women, 40–60 g/day for men), harmful
alcohol drinking (>40 g/day for women, >60 g/day for men)
and ﬁnally alcohol dependence, which refers to a cluster of
physiological behavioural and cognitive phenomena in
which the use of alcohol takes on a much higher priority
for a given individual than other behaviours that once had
a greater value [72].
The reported prevalence of alcohol consumption in the
transplant population is high, but both harmful drinking and
alcohol dependence are low at ∼1.5% [73].
We found one retrospective multivariate analysis, based
on data from the United States Renal Data System (USRDS)
[74]. In this study, alcohol consumption was deﬁned as a
dichotomous variable: ‘alcohol dependence’ declared as yes
or no at the time of the ﬁrst visit to an end-stage kidney
disease service. After adjustment for multiple covariates,
‘alcohol dependency’, was associated with an increased risk
of death (HR: 1.56 95% CI: 1.21–2.02) and death-censored
graft-loss (HR: 1.38, 95% CI: 1.04–1.08). It was reported
that the increased risk was not present in females; however,
this was not formally analysed due to sample-size restric-
tions. We found one additional retrospective single-centre
cohort study, in which both patient and graft survival up to
10 years after transplantation were numerically better for
patients with prior history of alcohol dependency [75].
Small numbers and univariate analysis make interpretation
of these results cumbersome. We did not ﬁnd any study
evaluating the inﬂuence of known alcohol consumption of
any category before transplantation on patient adherence
and drug-interactions afterwards. Also no studies were
found on success of alcohol cessation programmes or risk
of relapse after transplantation.
We found three old retrospective cohort studies evaluat-
ing the inﬂuence of past drug, heroin or cocaine abuse con-
ducted in 424 kidney transplant recipients. Results are
conﬂictive, studies underpowered and generally poorly de-
signed and analysed. Overall there is no evidence that past
heroin or cocaine abuse is associated with poorer patient
and graft survival. However, as these data come from obser-
vational studies, this only indicates that in well selected past
heroin or cocaine abusing patients, where the treating phys-
icians judged transplantation feasible, outcome is not jeo-
pardized [75–77].
How did we translate the evidence into the statement?
Although results come from one retrospective study with a
potential for misclassiﬁcation due to a vague deﬁnition of
alcohol dependency, we judged this would have biased
the results in favour of no difference, rather than that it
would have resulted in an overestimation of the effect. Ac-
cordingly, the guideline development group recommend that
patients with harmful drinking should reduce their alcohol
intake, and that patients with alcohol dependence should
stop. There is no evidence that modest alcohol consumption
negatively inﬂuences patient or graft survival, so complete
alcohol abstinence seems, in view of its wide social accep-
tance, neither realistic, nor necessary. However, the guide-
line development group judged that patients with alcohol
dependence as deﬁned by the WHO, have a high risk for
negative outcomes, and that, according to the deﬁnition and
the data in the general population, a sustained modest con-
sumption is not realistic in this patient group. Accordingly,
these patients should stop their alcohol consumption
completely.
The mechanisms by which alcohol consumption is associ-
ated to graft dysfunction are poorly understood. Alcohol-de-
pendent patients may have lifestyle habits that adversely affect
patient and graft survival. Levels of immunosuppressant drugs
might be very variable due to non-adherence with post-trans-
plant treatment, and because of pharmacokinetic interactions.
However, none of these mechanisms have been investigated
so far.
The few available data on the inﬂuence of drug abuse on
outcome after transplantation indicate that a history of heroin
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recipient survival. In all of these studies however a well-docu-
mented complete abstinence was a prerequisite for transplan-
tation. Accordingly, the guideline development group judged
that drug addicts should be encouraged to follow a structured
rehabilitation programme. The prospect of transplantation can
be used as a positive motivator.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
Studies, stratiﬁed for quantity of alcohol consumption and
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1.7. Does pre-transplant tobacco smoking in patients inﬂu-
ence patient or graft survival?
We recommend patients stop smoking before transplan-
tation. (1B)




Cigarette smoking increases the risk of cancer and cardiovas-
cular disease in the general population and may negatively
inﬂuence patient and graft survival in kidney transplant
recipients.
What did we ﬁnd?
Few studies have speciﬁcally addressed the role of pre-trans-
plant tobacco exposure on post-transplant outcomes.
However, many retrospective cohort studies have analysed
risk factors for post-transplant cardiovascular disease con-
trolling for pre-transplant tobacco exposure. All have shown
that tobacco exposure is associated with a decrease in
patient (HR: 1.4–7.4) and/or graft survival (HR: 1.3–8.1)
[78–109]. In addition, smoking cessation for 5 years or
more before transplantation has been associated with im-
provements in both patient (HR: 0.71, 95% CI: 0.52–0.9)
and graft survival (HR: 0.66, 95% CI: 0.52–0.85) [95]. One
study speciﬁcally in living donor kidney transplantation
showed that any history of smoking was associated with im-
paired graft and patient survival and a 50% increased risk
of early rejection [102].
How did we translate the evidence into the statement?
The evidence for a negative inﬂuence of smoking on the
outcome of kidney transplantation is large and consistent
stemming from well-adjusted multivariate analyses of observa-
tional data at low risk of bias. However, there was no consen-
sus in the guideline development group to consider active
smoking as a contraindication for waitlisting for transplan-
tation. The major argument was that it is very difﬁcult, if not
impossible to check smoking status, and even if patients
stopped smoking before transplantation, there is always the
risk of relapse after transplantation. There was however a con-
sensus to strongly recommend smoking cessation in kidney
transplant candidates. The guideline development group feels
that, as for the general population, success of smoking cessa-
tion can be enhanced by offering structured smoking cessation
programmes.
What do the other guidelines state? The UK Renal Asso-
ciation supports these recommendations [28]. No other guide-
line bodies provide a statement on this topic.
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1.8. Should obesity preclude waitlisting for kidney trans-
plantation and is there a difference in outcomes post-trans-
plantation between those with and without obesity?
We recommend that patients with a body mass index




There is uncertainty around the relation between obesity and
outcomes after kidney transplantation. Obese kidney trans-
plant recipients may have poorer outcomes in comparison
with non-obese recipients, but perhaps outcomes are better
compared with remaining on dialysis. There is no consensus
on whether obesity should be an exclusion criterion for kidney
transplantation and policies differ among transplant centres.
What did we ﬁnd?
We found 13 observational studies examining the relation
between obesity and outcomes after transplantation [110–
122]. All used BMI as a measure to discriminate between
obese and non-obese recipients, but studies differed widely in
their threshold for obesity, and the distinction between differ-
ent levels of excess weight.
All but one [119] were retrospective in design and included
between 130 and ±52 000 kidney transplant recipients. In nine
studies, multivariate Cox-regression analysis was used to
model time to event data [110, 112, 113, 116–119, 121, 122].
Results varied widely.
Whereas in three studies there was a signiﬁcant negative associ-
ation between obesity and death [117, 119, 121], graft loss or
death-censored graft loss, in six others results were inconclusive.
The difference could not be explained by sample size, variation
in the overall risk of bias or the extent to which estimates were
adjusted for confounding. However, deﬁnition of the reference
category and stratiﬁcation of obesity could be an explanation. In
the two studies in which authors distinguished between obesity
and morbid obesity (n = 79 304), morbid obesity was consist-
ently associated with a 20% increase in the risk of death and an
20% increase in the risk of graft loss, compared with a reference
category of normal weight recipients [116, 121]. Obesity—as
deﬁned by a BMI between 30 and 35 kg/m2—was not consist-
ently associated with poorer outcomes. Results differed accord-
ing to how patient groups were pooled and according to which
groups were compared with one another.
One study found obese recipients to have a 75% increased risk
of developing new onset diabetes after transplantation in com-
parison with non-obese recipients [112]. Finally one study
examined perioperative complications and found obese
patients to have 4% more surgical wound breakdowns.
However, there was no increase in the number of infections or
complete wound dehiscence when corrected for confounders
[118].
How did we translate the evidence into the statement?
The present data on the association between obesity and
patient and graft survival are conﬂictive.
Although morbidly obese patients have poorer outcomes after
transplantation than those who are not obese, the risk of mod-
erate obesity is less clear. Although one could hypothesize on
how obesity causally relates to adverse outcomes, we could not
identify interventional trials examining the effect of inten-
tional weight loss before transplantation on outcomes after
transplantation. In addition, in all of the studies obesity was
deﬁned as a BMI ≥30 kg/m2, and yet it is undeniable that
some individuals may have increased BMI which is not only
due to excess body fat. Finally, registry data have indicated
obese patients to beneﬁt from transplantation, with better sur-
vival compared with remaining on the waiting list [120, 123,
124].
With this in mind, the guideline development group felt that
they could not make a statement regarding the acceptance or
refusal for kidney transplantation based on obesity in itself.
On the other hand, candidates with morbid obesity do have
poorer outcomes after transplantation than those with a
normal weight. Although there is no evidence that weight
reduction before transplantation improves survival afterwards,
it seems reasonable to believe the cardiovascular risk proﬁle
would beneﬁt from such an intervention. How weight loss
should be achieved is less clear. Although the beneﬁts of
dietary treatment will reasonably outweigh the harms, both
pharmacological therapy and bariatric surgery will likely cause
more adverse events, making the risk–beneﬁt balance more
problematic.
What do the other guidelines state?
No other guideline body provides recommendations on
this topic.
Suggestions for future research
Randomized controlled trials to examine the beneﬁts and
harms of interventions aimed at losing weight in obese and
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1.9. Should kidney transplantation be delayed in patients
presenting with uncontrolled secondary hyperparathyroid-
ism? Does uncontrolled secondary hyperparathyroidism in
the immediate pre-transplant period have an impact on
transplant outcomes?
We recommend not refusing a cadaveric graft only because
of uncontrolled hyperparathyroidism in the recipient. (1D)
However, for patients on the waiting list, effort should
be made to comply with existing chronic kidney disease—
metabolic bone disease guidelines, including parathyroi-
dectomy, when indicated. (Ungraded Statement)
Rationale
Why this question?
There is evidence that parathyroid hormone (PTH) concen-
trations both early and late after kidney transplantation are inde-
pendently related to PTH levels before transplantation [125]. In
addition, persistent hyperparathyroidism following kidney trans-
plantation plays a central role in post-transplant hypercalcaemia
through calcium release from bone. As such, there might be a
risk of accelerated osteoporosis and vascular calciﬁcation, and of
nephrocalcinosis potentially leading to graft loss.
What did we ﬁnd?
Resolution of pre-transplantation hyperparathyroidism in the
post-transplantation period is reported to be rather uncom-
mon (22.7–50%) in several single-centre retrospective cohorts
[125, 126].
Two studies have shown that nephrocalcinosis detected by
protocol biopsies 3–6 months after transplantation is related
to persisting hyperparathyroidism and higher serum calcium
levels post-transplantation. In addition, early nephrocalcinosis
detected by protocol biopsies 3–6 months after transplantation
inﬂuenced graft function 1 year after transplantation in one
study, but not in a prospective study with a mean follow-up of
33 months [127, 128].
In a single-centre retrospective cohort study, pre-transplant
PTH levels were independently associated with death-censored
graft survival and with acute rejection, but not with patient
survival [129]. In the same study, pre-transplantation para-
thyroidectomy was independently associated with a 3-fold risk
reduction for death.
In a retrospective analysis, 49 patients with post-transplant hy-
perparathyroidism had similar graft survival compared with
those without hyperparathyroidism (88 versus 84%, P = 0.51)
[130]. In this study patients who underwent parathyroidect-
omy after transplantation had lower glomerular ﬁltration rates
(GFRs) (46 ± 20 versus 58 ± 21 mL/min, P = 0.04) and poorer
graft survival (71 versus 88%, P = 0.06) in comparison with
those that did not undergo parathyroidectomy.
In a small (n = 7) non-randomized observational study, total
pre-transplant parathyroidectomy with auto transplantation of
a small part of the gland resulted in better preservation of
bone mineral density as assessed by dual energy X-ray absorp-
tiometry (DEXA) testing post-transplantation [131].
In a single-centre prospective cohort study, PTH levels were inver-
sely associated with bone mineral density before transplantation.
However, evolution of bone mineral density post-transplantation
was not inﬂuenced by the pre-transplant PTH level [132].
Patients receiving calcimimetics before transplantation to
control severe secondary hyperparathyroidism who discon-
tinue the treatment after transplantation may be at risk of
rebound hyperparathyroidism, hypercalcaemia and early ne-
phrocalcinosis.
How did we translate the evidence into the statement?
The guideline development group judged that there was insufﬁ-
cient evidence to refuse only because of uncontrolled hyperpar-
athyroidism a cadaveric graft to a patient for whom a kidney
becomes available, as studies reporting on the association
between pre-transplantation PTH concentrations and graft survi-
val are conﬂictive, whereas all studies report absence of an associ-
ation with patient survival. The guideline development group
deems that the risk of delaying transplantation in these patients
outweighs the risks of transplantation with high PTH levels.
The guideline development group points out that this should
not be seen as an excuse not to do any effort to comply with
the guidance provided by KDIGO [133] and endorsed by
ERBP [134] with regard to management of metabolic bone
disease for the following reasons:
Complete resolution of hyperparathyroidism after transplan-
tation occurs rather infrequently.
There appears to be a higher prevalence of nephrocalcinosis in
patients with persistent hyperparathyroidism after kidney
transplantation, although this may have no inﬂuence on graft
outcome.
Parathyroidectomy before transplantation in patients with
hyperparathyroidism reduced the relative risk of death after
transplantation 3-fold, whereas parathyroidectomy after trans-
plantation seems to be associated with worsening graft function.
It should be taken into account that there is a high recurrence
rate of hyperparathyroidism and hypercalcaemia post-trans-
plantation in patients whose hyperparathyroidism was con-
trolled by calcimimetics before transplantation [135]. In
patients who are deemed suitable for kidney transplantation,
the risk of parathyroidectomy is low, while it probably is ben-
eﬁcial. Therefore, in patients who are listed on the waiting list,
and who have secondary or tertiary hyperparathyroidism,
parathyroidectomy in the pre-transplant period should be pre-
ferred over controlling PTH with calcimimetics.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
Inﬂuence of pre-transplantation parathyroidectomy in
patients with hyperparathyroidism listed for kidney transplan-
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1.10. How should screening for potential cardiovascular
disease in the potential recipient be done in a cost-effective
way?
We recommend that basic clinical data, physical examin-
ation, resting electrocardiogram (ECG) and chest X-ray are
a sufﬁcient standard work-up in asymptomatic low-risk
kidney transplant candidates. (1C)
We recommend performing a standard exercise toler-
ance test and cardiac ultrasound in asymptomatic high-risk
patients (older age, diabetes, history of cardiovascular
disease). In patients with a negative test, further cardiac
screening is not indicated. (1C)
We recommend performing further cardiac investigation
for occult coronary artery disease with non-invasive stress
imaging (dobutamine stress echocardiography or myocar-
dial perfusion scintigraphy) in kidney transplant candidates
with high risk and a positive or inconclusive exercise toler-
ance test. (1C)
We recommend performing coronary angiography in
kidney transplant candidates with a positive test for cardiac
ischaemia. Further management should be according to
the current cardiovascular guidelines. (1D)
Rationale
Why this question?
Cardiovascular death with a functioning graft is considered a
prevalent major negative outcome after kidney transplantation.
As a consequence, it is tempting to screen patients listed for
transplantation thoroughly for cardiovascular disease.
The American College of Cardiology/American Heart Associ-
ation (ACC/AHA) does not recommend routinely screening
asymptomatic patients facing intermediate to high-risk surgery
if their functional status allows them to perform four or more
metabolic equivalent tasks; however, the relevance of these ﬁnd-
ings to patients with end-stage kidney disease is not known. As a
consequence, ACC/AHA guidelines are in conﬂict with current
practice in many units for end-stage kidney disease patients
facing kidney transplant.
The question is of relevance, as not screening can incur an in-
creased risk of cardiovascular morbidity and/or mortality,
especially of death with functioning graft. On the other hand,
screening might deny a transplant to patients who might beneﬁt
from it, can substantially postpone the transplantation, and may
lead to increased costs and potential complications.
In addition, it is also unclear what to do when cardiac lesions
are found during screening, with regard to the different thera-
peutic options, and with regard to whether or not patients can
be put on the waiting list after their cardiac problem has been
intervened upon.
To properly assess the question at hand, a decision-tree analy-
sis should be made, where all components of underlying epi-
demiology, diagnostic accuracy of the different tests in
different subsets of patients, outcome of different interven-
tions and outcomes after transplantation of all these possible
combinations of events are numerically assessed. Such a
decision-tree analysis is a tremendous and complex task.
Therefore, the guideline development group decided to refor-
mat the problem into some easier to solve subquestions:
(1) Is it safe in asymptomatic patients at low risk to only
screen for cardiovascular risk by physical examination,
ECG and chest X-ray?
(2) What is the negative predictive value of non-invasive
tests such as a cardiac exercise tolerance test in asympto-
matic patients with a higher risk (diabetes; older age,
history of cardiovascular disease)?
(3) What is the negative predictive value of non-invasive
tests such as myocardial perfusion tests or dobutamine
stress echocardiography?
By providing the answers to these questions, we hoped to sub-
stantially simplify screening for cardiovascular risk in trans-
plant candidates, and reduce the number of patients in need of
a coronary angiography, without putting them at jeopardy. As
an additional question, we wondered whether there are cardiac
tests predictive for increased cardiac mortality due to non-cor-
onary artery disease.
What did we ﬁnd?
Several smaller single-centre cohort studies reported a high
negative predictive value for cardiovascular risk obtained by
basic history, clinical information, ECG and chest X-ray in
non-diabetic, asymptomatic patients [136–138]. Most of the
studies consider diabetes, presence of peripheral vascular
disease, older age, hypertension and elevated low-density lipo-
protein cholesterol as ‘high risk’.
In a retrospective analysis, Kasiske et al. found that in kidney
transplant candidates, who were considered low risk (43% of
the cohort) based on history, ECG and clinical ﬁndings, and
who were thus accordingly not further screened by invasive
testing, the actuarial incidence of an event related to ischaemic
heart disease was only 5.8% at 5 years after transplantation
[139]. In contrast, in patients deemed to be at high risk, and in
whom further investigation and work-up was performed, pro-
phylactic angioplasty was performed in 6.2%, and bypass
surgery in 2.8% before listing, but still, prevalence of an ischae-
mic heart disease-related event was 18.9% at 5 years.
Manske et al. reported that 31 out of 151 (20.5%) asympto-
matic insulin-dependent diabetic kidney transplant candidates
had coronary artery stenoses >75%. Of these, 26 were random-
ized to medical versus coronary bypass; 10/13 in the medical
versus 2/13 in the intervention group had a cardiovascular
event after a median of 8.4 months (P = 0.002), and 4 versus 0
patients died (P >0.05) [140]. In another study by the same
group in diabetic type 1 kidney transplant candidates, the
combination of age <45, non-smoking, no ST-segment
changes on ECG and <25 years of diabetes resulted in a nega-
tive predictive value for cardiac events of 98% [141]. At 36
months of follow-up, 55 and 30 % of those with >50% or
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De Lima et al. reported on a cohort of 1025 patients who were
screened in a pre-transplant work up by laboratory tests,
resting electrocardiography, transthoracic echocardiography
and non-invasive coronary testing [myocardial scintigraphy
with dipyridamole, single photon emission computed
tomography (SPECT)], irrespective of symptoms [143].
Patients in whom these tests revealed an increased probability
for the presence of coronary artery disease (n = 519, 51%) were
referred for coronary angiogram, where the presence of coron-
ary artery disease was conﬁrmed in 230 (44%). Based on the
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ACC/AHA criteria, these patients were either maintained on
medical therapy or referred for revascularization. Event-free
survival for patients on medical therapy at 12, 36 and 60
months was 86, 71 and 57%, whereas overall survival was 89,
71 and 50% in the same period, respectively. However, patients
who refused intervention had a worse outcome compared with
those who actually underwent intervention (cardiac events:
HR: 4.50, 95% CI: 1.48–15.10; death: HR: 3.39, 95% CI: 1.41–
8.45). Although these are observational data, they suggest that
∼50% of patients presenting for kidney transplantation can be
safely screened by basic non-invasive screening; for the other
50% who will need a coronary angiogram, about half will need
intervention based on ACC/AHA criteria, and half can be
maintained on medical therapy; overall, outcomes in these
groups should be considered equal. Refusal of treatment in
patients needing it based on the ACC/AHA criteria was detri-
mental however, and maybe these patients should be excluded
from the waiting list.
In a single-centre cohort study, 45/429 (10.5%) had a cardiac
event post-transplantation [144]. The risk was higher (31.3
versus 6.5%) in the subgroups with versus without pre-trans-
plant angina, myocardial infarction or positive angiography.
Five-year patient survival was lower in the high-risk group (82.8
versus 93.1%, P = 0.004), as was 5-year overall graft survival
(74.8 versus 84.1%, P = 0.08). Forty-one per cent of patients
who were treated with angioplasty plus stenting or bypass graft
prior to transplantation had post-transplant cardiac events,
when compared with 28% of those without intervention in the
high-risk group and 6.5% of patients in the low-risk group
(P = 0.001).
Koch et al. found a prevalence of coronary artery disease of
36% in diabetic patients; the presence of coronary artery
disease was poorly predicted by any clinical or biochemical
sign or by ECG; no outcome data were provided however
[145].
Barrionuevo reported a prevalence of relevant coronary artery
disease in 89/356 patients evaluated for kidney transplantation
[146]. Of these, 73 were asymptomatic; no outcome data were
reported. Charytan et al. evaluated 67 asymptomatic haemo-
dialysis patients with coronary angiogram, and found stenoses
in the proximal vessels in 28.5% [147]. The presence of this
ﬁnding was associated with increased 3-year mortality (HR:
3.1, 95% CI: 1.4–7.3).
When it comes to diagnostic accuracy of non-invasive tests de-
tecting signiﬁcant coronary artery disease, we found one well-
conducted systematic review, published in 2011. It included
eleven studies (690 participants) evaluating dobutamine stress
echocardiography, 7 studies (317 participants) assessing myo-
cardial perfusion scintigraphy, and two studies (129 partici-
pants) evaluating exercise stress electrocardiography.
Compared with coronary angiography, dobutamine had
pooled sentitivity of 0.80 (95% CI 0.64 to 0.90) and speciﬁcity
of 0.89 (95% CI 0.79 to 0.94). Myocardial perfusion scintigra-
phy had pooled sensitivity of 0.69 (95% CI 0.48 to 0.85) and
speciﬁcity of 0.77 (95% CI 0.59 to 0.89). Indirect comparison
suggested that dobutamine stress echocardiography may have
higher accuracy compared with stress echocardiography
(P = 0.07). Power to detect differences in accuracy at the 5%
level however was low due to sparse data [148].
In a study including 600 patients, most of them diabetics, the
42-month cardiac event-free survival rate was 97% in patients
with normal SPECT images and 85% in patients with abnor-
mal SPECT images (RR: 5.04, 95% CI: 1.4–17.6) [149], com-
parable with results reported in other studies [150, 151]. In a
cohort of 150 transplant candidates, using a multivariate logis-
tic regression model adjusted for age and diabetes mellitus, an
abnormal myocardial perfusion imaging test result (either low
left ventricular ejection fraction or abnormal perfusion), was a
strong independent predictor of all-cause mortality (OR: 2.5,
95% CI: 1.2–5.3), together with diabetes mellitus (OR: 2.2,
95% CI: 1.01–4.8) [152].
Hage et al. investigated all-cause mortality in 3698 patients
with end-stage kidney disease evaluated for kidney transplan-
tation [153]. Sixty per cent were high risk, but coronary angio-
graphy was performed in only 7%. The presence and severity of
coronary artery disease on angiogram was not predictive of
mortality. Coronary revascularization did not impact survival
except in three-vessel disease (P = 0.05).
In a study including 300 consecutive patients with end-stage
kidney disease referred for pre-transplant cardiac evaluation
(222 ﬁnally listed on the waiting list, 80 transplanted during
the follow-up), patients unable to exercise (Bruce standard ex-
ercise tolerance test) or to exercise for a maximum of 6 min ex-
hibited a higher mortality rate after transplantation in the
multivariate analysis (adjusted HR: 6.4 and 5.2, respectively,
P < 0.05) [154]. However, coronary angiography and revascu-
larization were not predictive of mortality.
In a cohort of 653 kidney transplant candidates, a left ventricu-
lar ejection fraction <45% was associated with a 1.8-fold in-
creased risk of cardiac complications and a 2-fold increased
risk of mortality after a mean follow-up of 3.0 ± 1.8 years [106].
In another study, four independent predictors of mortality
after kidney transplantation were identiﬁed: age >50 years
(P = 0.002), left ventricular end-systolic diameter >3.5 cm
(P = 0.002), maximal wall thickness >1.4 cm, (P = 0.014) and
mitral annular calciﬁcation (P = 0.036). The 5-year survival es-
timates for 0, 1, 2 and 3 prognostic factors were 96, 86, 69 and
38%, respectively [155].
In an observational cohort of 253 transplant candidates
deemed to be at high cardiovascular risk, mortality was worse
in patients not transplanted versus transplanted, even after
stratiﬁcation for the severity of coronary artery disease.
However, it is unclear how lead time bias induced by death on
the waiting list inﬂuenced these results, and the data should be
interpreted with caution [156].
How did we translate the evidence into the statement?
The guideline development group proposes an algorithms for
screening for underlying cardiovascular disease.
In patients with a low cardiovascular risk proﬁle, history,
basic ECG and chest X-ray have a very high negative predictive
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In patients with diabetes or high cardiovascular risk
(elderly, peripheral vascular disease, familial history),
additional stress testing has a high negative predictive value.
There is no clear evidence for superiority of one method of
stress testing over the other (dobutamine stress echocardiogra-
phy versus myocardial perfusion scanning, physical versus
medication induced exercise).
Only patients with high cardiovascular risk with non-nega-
tive stress imaging tests should undergo coronary arteriography.
A basic cardiac ultrasound can in high-risk patients give
some prognostic information, based on simple criteria.
What do the other guidelines state?
The UK Renal Association similarly does not recommend
full/invasive cardiac work up in asymptomatic patients [28].
KHA-CARI endorses similar recommendations on cardiac
work-up before transplantation [157]. The European Associ-
ation of Urology recommends to rule out coronary artery
disease in high-risk patients and to perform any revasculariza-
tions prior to transplantation [29].
Suggestions for future research
A randomized controlled trial comparing routine coron-
ary screening in asymptomatic high-risk patients with care
as proposed by the ACC/AHA guidelines would determine
whether current recommendations have an impact in out-
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1.11. When and for which indications should native ne-
phrectomy be performed in kidney transplant candidates
awaiting kidney transplantation?
We recommend native nephrectomy before transplantation
(unilateral or bilateral) in patients with autosomal poly-
cystic kidney disease (ADPKD) when there are severe, re-
current symptomatic complications (bleeding, infection,
stones). (1C)
We suggest unilateral nephrectomy of asymptomatic
ADPKD kidneys when space for the transplant kidney is
insufﬁcient. (2C)
We do not recommend routine native nephrectomy,
unless in cases of recurrent upper urinary tract infections or
when the underlying kidney disease predisposes to enhanced
cancer risk in the urogenital tract. (Ungraded Statement)
Rationale
Why this question?
There is no consensus regarding which kidney transplant can-
didates should undergo native nephrectomy, whether they
should undergo unilateral of bilateral nephrectomy and what
is the optimal timing for such a procedure.
What did we ﬁnd?
We identiﬁed 12 retrospective cohort studies examining the
inﬂuence of unilateral or bilateral nephrectomy on outcomes
after transplantation [158–169]. With the exception of one old
registry study including close to 3000 patients [166], sample
sizes were small with 23–75 participants each. Eight studies
only included patients with ADPKD [160–162, 164, 165, 167–
169].
In all 12 studies removal of one or both kidneys had been for
clear reasons of recurrent infections, persistent bleeding, dis-
comfort or lack of space for the kidney graft. In nine studies uni-
lateral or bilateral nephrectomy was compared with not
performing planned nephrectomy either before, during or after
transplantation (n = 3268) [158, 159, 161, 163–168]. Overall,
there was no difference in patient and/or graft survival between
patients who underwent nephrectomy before transplantation
and those that did not undergo planned nephrectomy.
When compared with patients who underwent planned ne-
phrectomy before transplantation, patients who underwent
planned nephrectomy during transplantation had similar
patient and/or graft survival after transplantation, post-operat-
ive complications and duration of hospital stay (ﬁve studies,
n = 2945). Complications and complication rates in case of re-
quired nephrectomy after transplantation were not different in
comparison with complication rate after planned nephrect-
omy. Only two small studies (n = 85) compared bilateral with
unilateral nephrectomy [162, 167]. Overall there was no evi-
dence to suggest outcomes after transplantation or compli-
cation rate differed between bilateral and unilateral
nephrectomy, but the comparisons were poorly studied.
All studies suffered from selection bias and lack of adequate
decision analysis as all studies only included those who were
actually transplanted.
How did we translate the evidence into the statement?
Overall there was no evidence to suggest that if kidneys were
left in place in asymptomatic patients, and surgeons did not
consider space to be insufﬁcient, patient or graft survival after
transplantation was compromised, complication rate was
higher or hospitalization was longer. If they did consider there
to be insufﬁcient space to accommodate the kidney graft, then
outcomes were not different whether the nephrectomy was
done before or during transplantation and whether one or
both kidneys were removed. Although subject to selection bias,
it suggests that subjecting these patients to an additional surgi-
cal procedure does not convey beneﬁt.
When one or both native kidneys were removed before trans-
plantation for reasons other than lack of space, it happened
because of recurrent infection, bleeding or pain. Reasonably,
the comparator group in whom kidneys were left in place had
no such symptoms. Outcomes were similar between those
with symptomatic and those with asymptomatic kidneys, pro-
vided the symptomatic kidneys had been removed and patients
had lived up to transplantation. Although there is no direct
evidence to support removal of symptomatic ADPKD kidneys
speciﬁcally in light of subsequent transplantation, it seems
reasonable the strategy would not differ from those who are
not considered for transplantation. The guideline development
group felt that although not supported by direct evidence, the
risk of severe infections under immunosuppression in patients
with recurrent urinary tract infections before transplantation
could make nephrectomy of a non-ADPKD kidney a reason-
able strategy.
What do the other guidelines state?
These recommendations are in line with those of the Euro-
pean Association of Urology. None of the other guideline
bodies provides a statement on this topic [29].
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CHAPTER 2 . IMMUNOLOGICAL WORK-UP
OF KIDNEY DONORS AND RECIPIENTS
2.1. How should HLA typing be performed in kidney
transplant candidates and donors?
We suggest that at least one typing is performed by mol-
ecular HLA typing of patients and donors to avoid mistakes
in the classiﬁcation of the HLA antigens. (2D)
We suggest that HLA typing is performed in duplicate,
preferentially on separate samples obtained at different
occasions to avoid logistical errors. (Ungraded Statement)
In case of sensitized patients, we recommend additional
serological typing of the donor cells to be used for cross-
matches in order to check the proper expression of the
HLA antigens on the target cells. (1D)
For highly sensitized patients with allele-speciﬁc anti-
bodies we suggest to consider high-resolution molecular
typing in both recipients and donors. (2D)
Rationale
Why this question?
Good matching potentially improves graft outcome. More
precise tests may improve the matching, and thus improve
graft outcome. However, they are expensive and laborious.
What did we ﬁnd?
All studies comparing the results of serological HLA typing
and molecular typing show a signiﬁcantly lower discrepancy
rate with molecular typing irrespective of the molecular typing
technique, i.e. PCR-SSP and PCR-SSO. Especially serological
typing for HLA-DR is associated with a high discrepancy rate
up to 25% but also for HLA-A and -B typing the error rate is
signiﬁcantly higher when using serological typing [170–173].
The clinical beneﬁt of molecular typing is shown by studies
where patients had been transplanted with an HLA compatible
donor on the basis of serological typing. One-year graft survi-
val in the group that was also compatible after molecular
typing was signiﬁcantly higher (87 versus 72%, P < 0.05) than
in the group where molecular typing revealed incompatibilities
[174]. Of course, these data stem from an era with less potent
immunosuppressive regimens.
A disadvantage of molecular typing is the fact that this technique
does not test the proper expression of the HLA molecules on the
cell surface. This is important when cross-matches are per-
formed for sensitized patients as this may lead to false-negative
cross-matches in case the target antigen is not adequately ex-
pressed on the donor cells used for cross-matching. Serological
typing will reveal the expression of the antigens on the donor
cells used in the cross-match.
Matching in kidney transplantation is based on low-
resolution typing, which means that allelic mismatches could
still be present in apparently fully HLA-matched combi-
nations. High-resolution typing can reveal allelic differences
between donor and recipient, which may be important for
patients with allele-speciﬁc antibodies.
How did we translate the evidence into the statement?
Despite the fact that there is no direct evidence to prove super-
iority of molecular typing tests, the guideline development
group judged that they can be of beneﬁt because of better accu-
racy and reproducibility in deﬁning class I and class II anti-
gens.
For highly sensitized patients, high-resolution molecular
typing in both recipients and donors is necessary to avoid allo-
cation of kidneys bearing the HLA allele against which the re-
cipient has antibodies.
Duplicate sampling is recommended to avoid administrative
and logistic errors.
What do the other guidelines state?
The British Transplant Society endorses guidelines for the
detection and characterization of clinically relevant antibodies
in allo-transplantation in collaboration with the British Society
for Histocompatibility and Immunogenetics. They recommend
assessing a patient’s HLA alloantibody proﬁle to delineate anti-
gens regarded as unacceptable for transplantation [62].
Suggestions for future research
To evaluate outcomes of molecular typing versus classic
typing, using an intention to treat approach, and with the out-
come measures patient survival, graft survival and waiting time.
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2.2. In a kidney transplant recipient, how should HLA
matching be used to optimize outcome?
We suggest matching for HLA-A, HLA-B and HLA-DR
whenever possible. (2C)
We recommend balancing the effects of HLA matching
with other parameters that affect patient and graft outcomes
when deciding the acceptance of a potential graft. (1D)
We recommend giving preference to an HLA identical
donor and recipient combination. (1B)
We suggest giving more weight to HLA-DR matching
than to HLA-A and HLA-B matching. (2C)
We recommend giving more weight to HLA matching in
younger patients, in order to avoid broad HLA sensitization
that might impair re-transplantation. (Ungraded Statement)
Rationale
Why this question?
Matching for HLA antigens can potentially improve graft out-
comes. However, it can increase waiting time for certain
patients, and it can negatively impact on cold ischaemia time
(CIT).
What did we ﬁnd?
The current role of HLA matching is controversial. Several epi-
demiological data from large registries show a beneﬁt with
regard to both acute rejection incidence and graft survival
when HLA antigens are matched [175–184]. This is in particu-
lar true for zero mismatch versus one or more mismatched
organs [185]. Other studies fail to demonstrate a difference in
rejection rates and graft survival according to HLA matching
[186–188]. Overall it seems that HLA matching has a ben-
eﬁcial effect on graft survival, declining with era of transplan-
tation from ∼15% after 5 years during the years 1985–94 to 2–
8% during the years 1995–2005 [189–191].
Eurotransplant data show that matching primarily for HLA-
DR can result in a simpler and more equitable allocation of
kidneys [192].
The effect of matching has to be balanced with other factors
like time on dialysis. Moreover, waiting for a well-matched
kidney can have negative effect on patient survival when com-
pared with earlier transplantation with a poorly matched
kidney [186].
An increasingly important criterion for HLA matching is to
reduce sensitization. This should be taken into consideration
when transplanting a donor with a mismatch of a frequent
HLA antigen in a younger recipient with a chance of needing a
re-transplant.
How did we translate the evidence into the statement
The guideline development group judges that the impact of
matching for HLA-A, -B and -DR is too important to be neg-
lected. This beneﬁcial effect is especially observed when a full
match is obtained. The impact of DR mismatches is stronger
than for HLA-A and -B.
However, also other factors such as estimated CIT, waiting
time on the transplant list, eventual technical problems related
to dialysis, difference or agreement between age and body size
of donor and recipient should be accounted when taking the
individual decision to accept an offered organ for a speciﬁc
patient.
In young patients, it should be considered that re-transplan-
tation might become necessary in the future. Therefore, one
should try to have an as optimal organ as possible, to enhance
longevity, and to avoid mismatches, to reduce the potential for
sensitization, which at a later stage might complicate re-trans-
plantation.
What do the other guidelines state?
No other guideline provides speciﬁc statements on this topic.
Suggestions for future research
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2.3. In kidney transplant candidates, what HLA antigens
and non-HLA antigens should be deﬁned in addition to HLA-
A, -B and -DR?
We recommend performing HLA-DQ, HLA-DP and
HLA-C typing of the donor only when the intended recipi-
ent has HLA antibodies against those antigens. (1D)
We do not recommend routine typing for major histo-
compatibility complex class I-related chain-A (MICA) and
other non-HLA antigens in either recipient or donor. (1D)
Rationale
Why this question?
Besides the classical HLA antigens, also additional HLA and
non-HLA antigens might have an impact on graft outcome.
Additional identiﬁcation of these antigens can however pose
logistical problems, and is laborious and expensive. It might
also lead to avoiding clinically irrelevant mismatches, and thus
increase waiting time in some patients.
What did we ﬁnd?
The effect of HLA-C matching has been poorly studied. As a
result of linkage des-equilibrium, HLA-C matching is strongly
linked with A and B matching. In a small (n = 104) retrospec-
tive cohort study, an unplanned and univariate analysis
showed association between HLA-C mismatching and acute
rejection. However there was no pre-speciﬁed hypothesis or
correction for multiple testing [184]. In a large cohort of 2260
deceased donor kidney transplantations, the Collaborative
Transplant Study (CTS) group found that HLA-C mismatch
was associated with signiﬁcantly decreased graft survival in
sensitized (2 MM: 70.3 ± 7.5%, 1 MM 79.6 ± 2.7%, 0 MM
87.7 ± 1.7%, P < 0.001) but not in non-sensitized patients
(P = 0.75) [193].
The inﬂuence of HLA-DP matching on transplant outcome
has still to be clariﬁed. Around 14% of the patients have HLA-
DP antibodies before transplantation [194]. Post-transplant,
5.1% of recipients of a functioning graft and 19.5% of those
who have rejected their graft have DP antibodies by Luminex
[195]. The CTS group has reported in a cohort of 3600 ﬁrst
transplantation and 1300 re-transplantation that HLA-DP
matching is not associated with better allograft survival after a
ﬁrst kidney transplant, but is associated with better 1-year
graft survival after a second kidney transplant (83 versus 76
versus 73% in 0, 1 and 2 mismatches respectively [196]. The
same team as well as the Leiden group showed later, by study-
ing the amino-acid residues in the hyper variable regions of
the DP alleles that matching for certain immunogenic epitopes
was more important than the classical matching at the allelic
level [194, 197].
Among non-HLA antigens, MICA is the strongest antigenic
system. While indirect evidence from small, retrospective
studies suggest that MICA antibodies could be a risk factor for
acute kidney graft rejection [196, 198–201], the most robust
though contradictory data in kidney transplantation stem two
major studies. In a cohort of 1910 transplanted patients, 11.4%
had MICA antibodies before transplantation [202] MICA
immunization signiﬁcantly correlated with acute rejection and
lower 1-year graft survival. Its inﬂuence was more evident in
ﬁrst transplantation and in patients well matched for HLA
with their donor. In the second study, MICA antibodies were
detected in 14.9% of patients with chronic kidney disease, 425
transplanted and 172 dialysed, versus 6.8% in controls [203].
The variables associated with their development were the
same as for HLA antibodies: transfusion, pregnancy and pre-
vious transplantation. Contrasting with the preceding study,
no detrimental effect of MICA immunization on graft survival
even at 10 years was found. In a subgroup of patients, MICA
antibodies were identiﬁed as autoantibodies in 20%.
The pathogenic role of H-Y has been demonstrated in two
large studies with a cohort of >100 000 transplantations, one
from the CTS group [204] and one from the United States
Renal Database [205]. Both found a signiﬁcantly increased risk
of graft failure in the combination male donor/female recipient
at 1 year but not at 10 years and female recipients even ap-
peared to have better survival whatever the sex of the donor.
Although signiﬁcant, the H-Y effect was small (HR: ∼1.03).
The US study included more covariates in the analysis such as
race, peak PRA, cause of end-stage kidney disease and trans-
plant era, but the conclusions were identical apart from a
trend to disappearance of the H-Y effect in patients trans-
planted between 2000 and 2004. Antibodies against two re-
combinant H-Y molecules have been identiﬁed by enzyme-
linked immunosorbent assay (ELISA) and western blot in 46%
of 26 female recipients of a male donor versus 0–3% in the
other sex combinations [206]. These antibodies signiﬁcantly
and strongly correlated with acute rejection, CD38 and CD138
plasma cell inﬁltrates in the biopsy but not with C4d staining
and post-transplant HLA antibody.
A signiﬁcant effect on acute rejection of certain killer immuno-
globulin-like receptor (KIR) mismatches has also been reported.
A recent study showed that in 137 kidney transplantations com-
patible for HLA-A, HLA-B and HLA-DR, KIR-ligand mis-
matching was associated with a 25% reduction in death-
censored graft survival (P = 0.043) [207] and was an indepen-
dent risk factor un-multivariate analysis (HR: 2.29). This effect
was estimated comparable with that of HLA-A and -B incom-
patibilities. In HLA-B incompatible transplantations, KIR-
ligand mismatches had no additional effect [208].
Other targets for non-HLA antibodies, such as endothelial cell
antigens [209], have been suggested but their interest in
kidney transplantation still has to be demonstrated. Antibodies
against the angiotensin II type 1 receptor (AT1) were reported
several years ago as able to induce humoral rejection charac-
terized by malignant hypertension in a small series of 16
patients [210]. However, in 28 patients from a cohort of 433
kidney transplants, having early antibody-mediated rejection,
none among the 10 that were not explained by HLA antibodies
were associated with AT1 antibodies [211]. Along this line,
AT1 antibodies could not be detected among patients who
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transferase T1 (GSTT1) antibodies have been described in
acute and chronic C4d-positive antibody-mediated rejection
in patients who do not have the GSTT1 gene (20% of the
population) and have received a GSTT1-positive donor [213,
214].
How did we translate the evidence into the statement?
Non-classical HLA types (HLA-C, HLA-DP and HLA-DQ)
have been associated with acute rejection and worse graft sur-
vival. However, most of these data come from older observa-
tional cohorts which might not be representative for current
transplant practice, and are based on univariate analyses.
Taking into account the rather limited effect size, and the
potential logistical consequences of routinely typing for these
additional HLA antigens, both in terms of ﬁnancial costs and
increasing the complexity of allocation, the guideline develop-
ment group recommend performing HLA-C, HLA-DP and
HLA-DQ preferentially in high-risk patients, i.e. re-transplan-
tation in highly sensitized patients.
We suggest neither screening for AT I-receptor antibodies
or MICA antibodies nor for any other non-HLA antibody.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
Prospective studies analysing the impact of matching for
HLA-DQ, HLA-DP and HLA-C should be undertaken, with
as outcome parameters patient and graft survival, time on the
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2.4. In HLA-sensitized kidney transplant candidates what
measures should be attempted to improve the probability of
a successful transplantation?
We recommend establishing programmes to select a
donor towards whom the recipient does not produce anti-
bodies. (1C)
In recipients from cadaveric kidney donors, this aim can
be achieved by an acceptable mismatch programme. (1C)
In living donation this goal can be achieved by paired
exchange. (Ungraded Statement)
We recommend transplanting patients with donor-speciﬁc
antibodies only if these above-mentioned measures cannot be
accomplished and after successful intervention. (2D)
Rationale
Why this question?
Patients can be HLA sensitized, which might jeopardize their
graft survival. Avoiding donors to whom the sensitized recipi-
ent produces antibodies can prolong the waiting time, or can
lead to abandoning living donation. Several interventions have
been described in the last decade to reduce the antibody titres,
allowing transplantation of patients with donor-speciﬁc anti-
bodies.
What did we ﬁnd?
In deceased donor transplantation, the Acceptable Mismatch
programme of Eurotransplant is based on the accurate deﬁ-
nition of the HLA antigens or epitopes against which the
patient has not formed antibodies; the donor must be compa-
tible with the combination of the HLA type of the recipient
and the acceptable antigens. This procedure has increased the
transplantation rate for highly immunized patients with good
results [215]. France has a similar programme where accepta-
ble antigens are deﬁned according to the positivity and
strength of the HLA antibodies by Luminex. In case an incom-
patible living donor is available, paired donor exchange pro-
grammes have shown to be a good tool to ﬁnd an alternative
cross-match negative donor [216].
Several papers have described a progressive or integrative ap-
proach in the attribution of the transplant graft and have also
speciﬁed the associated risk [217, 218]. The ﬁrst protocols were
based on high dose intravenous immunoglobulins (IVIG) [219]
or plasmatic exchange with low dose IVIG [220]. Stegall com-
pared both and reported a lower incidence of humoral rejection
whenever plasma exchange was used pre- and post-transplant
[221]. In some centres, plasma exchange has been replaced by
immunoadsorptions [222]. Anti-CD20 antibodies have been
added in the most recent protocols for inhibition of antibody
production [223, 224]. The association of rituximab, plasma ex-
change and IVIG has improved the access of immunized
patients to a transplant and short-term graft survival. In one
study including histological data, the addition of rituximab was
also shown to signiﬁcantly decrease the inﬂammatory lesions in
the microcirculation, the rate of transplant glomerulopathy and
of chronic humoral rejection [224]. Based on a publication of
the Mayo Clinic showing that this drug was able to inhibit anti-
body producing cells in the bone marrow [225], bortezomib has
been used in desensitization protocols, but results are equivocal.
A multicentre North American trial on this topic is currently
on-going. An original approach has recently been proposed by
Stegall with the addition of eculizumab, an anti-C5 monoclonal
antibody to reduce lesions associated with complement acti-
vation by donor-speciﬁc antibodies [226]. Although most of
these protocols reduce HLA antibodies to a degree that trans-
plantation becomes possible, the long-term outcome of these
procedures is still uncertain, as no study has a follow-up longer
than 3 years.
How did we translate the evidence into the statement?
In addition to poorer graft survival, HLA-sensitized patients,
especially the highly sensitized ones, have a poor access to
kidney transplantation and accumulate on the waiting list. The
search for a compatible donor should be preferred, and opti-
mized with the most accurate characterization of the HLA
antibodies and attribution of a suitable donor, living or de-
ceased, through speciﬁc programmes.
Transplantation of an HLA incompatible kidney should remain
the last step when the search for a compatible donor is unsuc-
cessful. HLA incompatible donors are increasingly proposed to
these patients, after elimination of the donor-speciﬁc antibodies
by desensitization procedures. These procedures allow trans-
plantation, and have a reasonable and acceptable short-term
outcome in reported case series. However, these interventions,
either applied alone or in combination, do not seem able to sig-
niﬁcantly and sustainably reduce donor-speciﬁc antibody pro-
duction in patients with high levels of HLA antibodies and
there is still concern in the long-term outcome of the transplant
and patient survival. Clearly, more studies are needed with
larger cohorts and longer-term endpoints.
The strength of HLA antibody titres under or above which de-
sensitization protocols are either not necessary or not efﬁcient
has also to be determined.
What do the other guidelines state?
The British Transplant Society together with the British
Society for Histocompatibility and Immunogenetics endorses
recommendations on HLA-speciﬁc antibody incompatible
transplantation in general (not speciﬁcally on kidney trans-
plantation) [62]. They recommend determining the HLA
speciﬁcity and level of donor-speciﬁc antibodies prior to anti-
body reduction treatment which should follow an established
clinical and laboratory protocol.
Suggestions for future research
Long-term follow-up observational studies reporting graft
and patient survival and complications with protocols bypass-
ing high sensitization are needed.
Head-to-head comparison of different protocols for
reduction of antibody titres is needed.
Relevant cut-off points for antibody strength should be
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2.5. Should in kidney transplant candidates a failed allograft
that is still in place be removed or left in place?
Evidence comparing patients with a failed transplant
with versus without nephrectomy is insufﬁcient and con-
ﬂictive, hampering a meaningful general recommendation
on whether or not nephrectomy of failed grafts should be
recommended. (Ungraded Statement)
We suggest that in following conditions an explantation
of the failed kidney graft be considered: clinical rejection,
chronic systemic inﬂammation without other obvious cause
or recurrent (systemic) infections. (Ungraded Statement)
We suggest to continue low level immunosuppression
and to avoid a nephrectomy of a failed graft when residual
graft urinary output is >500 mL/day and there are no signs
of inﬂammation. (Ungraded Statement)
Rationale
Why this question?
Failed graft is an increasingly prevalent reason for start of
kidney replacement therapy. Removal of a failed graft can
theoretically reduce the inﬂammation induced by on-going
activation of the immune system. The presence of the failing
graft might induce sensitization, which might hamper re-
transplantation. The net immunological effects of a nephrect-
omy are unclear, as the failed graft can act as a sponge of
already present antibodies, which will become apparent after
nephrectomy. In addition, nephrectomy deprives the patient
of residual diuresis, if still present.
What did we ﬁnd?
Several studies have compared rejection incidence and graft sur-
vival in re-transplant recipients with versus without the failed
graft in situ. All these studies showed serious methodological
limitations because they were single centre; the management of
immunosuppression both before and after nephrectomy varied
between reports; the indications of nephrectomy were non-stan-
dardized, some being performed electively and others because
of clinical indications; and there was a general lack of adjust-
ment for possible confounders such as co-morbidities or time
on dialysis before nephrectomy. Some studies did not show any
difference in rejection incidence and graft survival or rejection
incidence whether transplantectomy was performed or not
[227], whereas others show either a beneﬁcial [228] or a detri-
mental impact of previous transplantectomy [229, 230]. Early
data showed a higher anti- HLA sensitization if nephrectomy of
the failed graft occurred before instead of during re-transplan-
tation [231]. This was later conﬁrmed when the presence of
HLA antibody speciﬁcities in the serum of 65 patients from 16
centres was analysed before and after nephrectomy of the failing
graft [232]. In the HLA-A, HLA-B and HLA-DRB1 mismatch
categories the incidence of DSA reactivity pre- versus post-ne-
phrectomy was 64 versus 87% (P = 0.003) and 57 versus 86%
(P = 0.001), respectively. The frequencies of individual reactive
antigens were also lower before versus after nephrectomy of the
failing graft: for HLA-A and HLA-B antigens: 49 versus 75%
(P < 0.0001) and DRB1 antigens: 48 versus 79% (P = 0.0001).
The authors speculated that additional antibodies are probably
absorbed into the rejected graft and became apparent after
removal of the graft.
In a small (n = 21 and 32) retrospective single-centre cohort,
graft survival at 1, 3 and 5 years was 83 versus 89%, 64 versus
79% and 45 versus 68% in the nephrectomized versus non-ne-
phrectomized group, respectively. None of these differences
was signiﬁcant, which might be due to the lack of power [233].
In a small (n = 89) retrospective cohort study comparing
patients who had their failing graft removed (Group 1) versus
left in place (Group 2), there was no difference in panel reac-
tive antibody (PRA) titre at the moment of transplantation (37
versus 29%). After a mean follow-up of 4 years, 49.1% of
patients in Group 1 versus 31.2% in Group 2 had acute rejec-
tion (P = 0.20) and 20 (29%) versus 4 (19%) of grafts failed in
Group 1 versus Group 2; 1, 3 and 5 years’ actuarial graft survi-
val in Group 1 was 83.8, 76 and 66.2%, whereas in Group 2, it
was 94.7, 86.8 and 69.5%, respectively (P = 0.66). Five-year ac-
tuarial patient survival in Groups I and II was 94.1% and
87.5%, respectively (P = 0.69) [234].
In a large retrospective analysis of USRDS data, including
3707 early graft failure and 15 400 late graft failure patients
(graft survival >12 months), nephrectomy was associated with
an increased risk of death (HR: 1.13, 95% CI: 1.01–1.26) in the
early transplant failure cohort, whereas in patients with late
transplant failure, it was associated with a decreased risk of
death (HR: 0.89, 95% CI: 0.83–0.95) [235]. In early transplant
failure patients, nephrectomy was associated with a lower risk
of re-transplant failure (HR: 0.72, 95% CI: 0.56–0.94), while
among late transplant failure patients it was associated with a
higher risk (HR: 1.20, 95% CI: 1.02–1.41). In another analysis
of the cohort in the USRDS database between 1994 and 2004,
included 10 951 transplant recipients who returned to long-
term dialysis [236]. Of those, 3451 (31.5%) received an allo-
graft nephrectomy during the follow-up, which was associated
with a 32% lower-adjusted relative risk for all-cause death (ad-
justed HR: 0.68, 95% CI: 0.63–0.74), after adjustment for
socio-demographic characteristics, comorbidity burden, donor
characteristics, interim clinical conditions associated with re-
ceiving allograft nephrectomy and propensity to receive an allo-
graft nephrectomy. Those having versus not having a transplant
nephrectomy had a higher probability for re-transplantation
(10.0 versus 4.1%, P < 0.0001), but there might have been bias
by indication, and no outcome data for the re-transplant were
provided.
In a small retrospective comparison including only
patients who actually underwent re-transplantation, previous
nephrectomy (n = 141) versus no nephrectomy (n = 45) was
associated with increased panel reactive antibody titres (37.2
versus 17.8%, P = 0.02), increased rates of primary non-func-
tion (14.8 versus 4.4%, P = 0.05) and acute rejection (29.7
versus 13.6%, P = 0.04), and worse re-transplant graft survival
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Importantly, recent data show that, among patients who un-
derwent early graft nephrectomy and were left without immu-
nosuppression, anti-donor HLA antibodies were produced
only after several weeks and continued to increase up to 6
months after graft nephrectomy. This observation suggests
that donor-speciﬁc antibodies are produced ‘de novo’ after
graft nephrectomy, rather than absorbed by the graft and re-
leased in the circulation thereafter [237].
How did we translate the evidence into the statement?
Data seem to suggest that removal of a failing graft might
either lead to ‘de novo’ immunization to donor HLA antigens,
or reveal the presence of antibodies that where adsorbed by
the failing graft while still in place. Data on graft and patient
survival after re-transplantation are coming from small obser-
vational cohorts, and there is a substantial risk of bias by indi-
cation, as presumably, there was mostly a clear reason for
removal of the failing graft; however, data on indications for
graft removal are not available.
The guideline development group judged that data do not allow
to draw any meaningful general conclusion, and that the
decision for nephrectomy of a failed graft should be taken on a
case per case basis. Factors to be included in the evaluation are
the presence/absence of residual kidney function, and the pres-
ence or absence of inﬂammation or infection.
We suggest that the threshold to perform a nephrectomy
should be substantially lower in patients in whom re-trans-
plantation is not an option; in contrast, in patients rescheduled
for re-transplantation, the threshold should be higher.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
A randomized controlled trial comparing nephrectomy
with no nephrectomy of a failed graft should be performed,
with post-nephrectomy immunization proﬁle and kinetics,
patient survival, time to re-transplantation and graft survival
as outcomes. Such a trial should include an evaluation of the
impact of continuation of immunosuppression after transplant
nephrectomy. A separate analysis should be provided for
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2.6. In kidney transplant candidates, what technique of
cross-match should be used to optimize outcomes?
We recommend performing a complement-dependent
cytotoxic (CDC) cross-match in HLA-sensitized patients to
prevent hyperacute rejection. (1B)
We suggest that in HLA antibody negative patients with
negative regular quarterly screening samples a cross-match
can be omitted, unless a potential HLA-sensitizing event
has occurred since last screening. (2B)
We do not recommend performing a Luminex or endo-
thelial cell cross-match because their additional value
needs further evaluation. (1D)
We recommend a positive CDC cross-match should
only be accepted as truly positive when donor-speciﬁc anti-
bodies are known to be present. (1B)
Rationale
Why this question?
A cross-match is used as an in vitro test to evaluate compatibil-
ity between the individual donor and recipient pair. However,
performing the cross-match takes some time, and might in-
crease CIT.
CDC is the most widespread test, but more sensitive tests have
been developed over the last years. These tests are however
more laborious and expensive, and might lead to false-positive
results.
What did we ﬁnd?
Historical data show that a positive CDC cross-match due to
donor-speciﬁc HLA antibodies is associated with the occur-
rence of hyperacute rejection [238, 239]. The clinical relevance
of a positive CDC cross-match with historical sera only is less
clear and such a cross-match is rather a risk factor than a con-
traindication for transplantation [240]. A more sensitive
variant of the CDC cross-match is the one augmented by the
addition of anti-human immunoglobulin, the AHG-CDC
cross-match, which might be too sensitive for the mere pre-
vention of hyperacute rejection [241]. In order to detect anti-
bodies reactive with donor HLA class II, CDC cross-matches
are performed with B cells as target. The relevance of a positive
B-cell cross-match is less clear. Le Bas-Bernadet showed a
higher incidence of early graft failure in case of a positive B-
cell cross-match, whereas Pratico-Barbato did not observe any
clinical effect [242, 243]. The reason for this may be the speci-
ﬁcity of the antibodies causing the positive B-cell cross-match.
In case of a positive B-cell cross-match and proven donor-
speciﬁc antibodies in antibody screening a high incidence of
graft loss is observed whereas a positive B-cell cross-match in
the absence of DSA has no effect on graft outcome [244]. Not
all HLA antibodies do ﬁx complement, which is the reason
why the ﬂow cytometric cross-match was introduced. Several
retrospective studies show that the presence of a positive ﬂow
cytometric cross-match is not a contraindication for
transplantation but is associated with a higher incidence of re-
jection although many grafts function well without any com-
plications [245–248]. Other studies could not demonstrate any
clinical relevance of a positive ﬂow cross-match in the pres-
ence of a negative CDC cross-match [249–251]. A positive
ﬂow cross-match in the presence of donor-speciﬁc antibodies
a shown to be associated with more acute rejection and poor
graft function [246], although this was not conﬁrmed by a
small study by Bryan et al. [252]. A problem associated with
ﬂow cross-matching is the detection of irrelevant (non-HLA)
antibodies especially reactive with B-cells, which may be pre-
vented by the addition of pronase [253, 254]. Recently two
other cross-match tests have been introduced: one for the de-
tection of donor-speciﬁc HLA antibodies on the basis of the
Luminex technology [255], while the second one uses endo-
thelial cell precursor cells as targets in order to be able to
detect non-HLA targets [256].The clinical relevance of these
assays remains to be established.
Recent data suggest that a good antibody screening can help to
deﬁne non-acceptable mismatches and can predict a positive
cross-match [257–261]. Donors expressing these non-acceptable
HLA antigens can be excluded without performing an actual
cross-match, a policy called a virtual cross-match.
In a cohort of 606 patients [262], no cross-match was being
performed before transplantation in 257 non-sensitized
patients; a cross-match performed at a later stage proved to be
negative in all cases, and CIT was reduced from 16.7 to 14.3
hours, resulting in a decrease (28 versus 18%) in delayed graft
function (DGF) in recipients of a brain death donor, but not
in recipients of a heart-beating donor (52 versus 54%).
How did we translate the evidence into the statement?
A positive CDC cross-match with current serum is considered
a contraindication for transplantation. It is however essential
to take the results of antibody screening into consideration in
the interpretation of the cross-match. A positive B-cell cross-
match in CDC is therefore only associated with a higher inci-
dence of rejection when donor-speciﬁc antibodies are present.
If that is not the case, graft survival and rejection incidence in
patients with a positive B-cells cross-match are similar to that
of non-sensitized patients. An important aspect of the CDC
cross-match is the fact that donor lymphocytes are used as
target cells. The consequence is that the antibodies leading to a
positive cross-match are not necessarily directed against the
HLA antigens. This is one of the reasons that why a positive
cross-match in CDC is not always a contraindication for trans-
plantation.
In non-sensitized patients with negative regular quarterly
screening samples, the guideline development group accepted
that a cross-match can be omitted. This is based on a
large cohort of such patients, where in none of the cases, a
positive cross-match was observed at a later stage. In this
study, omission of the cross-match resulted in a shorter CIT,
and in the recipients of a brain death donor even in less DGF.
However, it is important that no potentially HLA sensitizing
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Positive cross-match tests based on ﬂow cytometry are associ-
ated with increased, but not unacceptable, risk of graft loss and
the guideline development group judged that transplantation
under these conditions is possible, but should be done with
caution. However, the guideline development group judged
that the additional value of ﬂow cytometry remains uncertain,
and that especially cost aspects make that it cannot be rec-
ommended as a routine procedure. The same line of reasoning
was followed for cross-match based on Luminex and on endo-
thelial cell assays.
What do the other guidelines state?
The European Association of Urology recommends that a
lymphocyte cross-match should be performed to avoid hyper-
acute rejection. The British Transplant Society in collaboration
with the British Society for Histocompatibility and Immuno-
genetics recommend pre-transplant cross-match unless a
programme exists to conﬁdently identify non-sensitized indi-
viduals that have never produced HLA antibodies [62]. Ac-
cording to them, patients with no detectable HLA-speciﬁc
antibodies can be transplanted on the basis of a negative
virtual cross-match without waiting for a cross-match test to
be performed; this recommendation is thus in line with that of
ERBP. Additionally, a cross-match using ﬂow cytometric tech-
niques on historic samples of the sensitized patient is rec-
ommended for sensitized patients.
Suggestions for future research
Further evaluation of the additional value of ﬂow cyto-
metric, Luminex and endothelial cell cross-match, including
health economic analysis is needed.
Further evaluation of the impact of omitting a cross-match
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2.7. In kidney transplant candidates planned to undergo
living donor transplantation but for whom the available
donor is ABO incompatible, what measures can be taken to
improve outcome after transplantation?
We recommend both inhibition of antibody production
and ABO antibody removal before transplantation applied
together in one and the same validated protocol. (1C)
We recommend transplantation of an ABO incompati-
ble kidney only if the ABO antibody titre after intervention
is lower than 1:8. (1C)




In some cases only an ABO blood group incompatible living
donor is available. Allowing ABO incompatibility in living
donation could expand the donor pool. However, there
might be an increased risk for rejection and worse long-term
outcomes.
What did we ﬁnd?
It has long been known that preformed anti-ABO antibodies
trigger hyperacute rejection, and ABO incompatibility has
been considered an absolute contraindication to kidney trans-
plantation. As a consequence, between 30 and 40% of potential
living donors are turned down. An extreme lack of available
deceased donor kidneys encouraged investigation into desensi-
tization for ABO incompatible living donation in Japan start-
ing in 1989, using antibody removal and splenectomy. At
present, the long-term results between ABO incompatible and
compatible transplantation are similar [263, 264]. One report
detailed the long-term follow-up on 441 of 494 patients who
received an ABO incompatible kidney allograft during the
period of 1989 through 2001. In this retrospective multicentre
analysis, there was no signiﬁcant difference in patient or graft
survival at Year 1, 3, 5, 7 or 9 compared with historical data
from 1055 recipients of ABO compatible living donor allo-
grafts [265]. In Europe, the median-term outcomes of 60 con-
secutive ABO incompatible kidney transplantations after the
use of a protocol that incorporated antigen-speciﬁc immu-
noadsorption, rituximab, and IVIG were compared to that of
276 ABO compatible live donor transplant recipients in three
centres [266]. At follow-up of up to 61 months, allograft survi-
val was 97% for the ABO incompatible group versus 95% for
the ABO compatible recipients. Patient survival was identical
for both groups (98 %). Of note, there was a signiﬁcant im-
provement in ABO incompatible graft survival in patients in
the 2000 to 2004 era, following the incorporation of tacrolimus
and mycophenolate in the maintenance immunosuppression
regimen instead of cyclosporine and azathioprine [267]. In
this analysis, statistically superior allograft survival in the most
recent period was reported at 1 year (94 versus 78%) and 5
years (90 versus 73 %); acute rejection rates had also markedly
improved (15 versus 48%). Along the same line, the combined
use of tacrolimus and mycophenolate mofetil allowed to safely
and efﬁciently transplant patients who had initial high titres
against A and/or B antigens, in contrast to similar patients
previously transplanted under cyclosporine and azathioprine
[268].
In most recent reports, the incidence of early acute antibody-
mediated rejection is below 10%, and is similar to that ob-
served after ABO compatible transplantation [266, 269–276].
The main principles to allow for efﬁcient ABO incompatible
transplantation are ﬁrst, to reduce circulating ABO antibody
titters with either plasmapheresis or immunoadsorption, with
the goal of achieving titters≤ 1:8 to≤ 1:32, depending on
centre practice [277]. When plasmapheresis is used, most
centres administer 0.1 g/kg of intravenous immunoglobulins
(IVIG) after each session [274, 278–284] in order to avoid the
depletion of protecting antibody and also to take advantage of
the immunomodulatory properties of IVIG [285].
Immunoadsorption was initially described in Sweden using
an afﬁnity column coated with A and B blood group antigens
(Glycosorb A/B®, Glycorex Transplantation AB, Sweden), al-
lowing for speciﬁc depletion of anti-A/B antibodies [286].
Immunoadsorption is performed daily until antibody titres
reach 1:8 or lower. In roughly 80% of patients this is achieved
with four sessions of antibody removal. This technique is
now widely and successfully used in Europe [269, 272, 287,
288]. Second, immunosuppression should be initiated at least
one week prior to transplantation, to inhibit the synthesis of
the anti-A/B antibodies depleted by immunoabsorption or
plasmapheresis. Third, splenectomy and the use of rituxi-
mab, the anti-B-cell depleting monoclonal antibody, have
been used as adjunctive therapies to further inhibit post-
transplantation antibody synthesis. Several protocols have
been published. However, what seems to be essential is the
reduction of ABO titres at the time of transplantation, to
avoid hyperacute rejection and early acute antibody-
mediated rejection during the ﬁrst post-transplant month.
Beyond this period, a rise in isoagglutinin antibody titre to
pre-treatment levels or higher is generally not associated with
graft damage, a process called accommodation. Although
controversial, splenectomy has been commonly used in de-
sensitization protocols for ABO incompatible transplantation
to reduce the risk of acute antibody-mediated rejection,
mostly in Japan [265, 283, 289, 290] but also in the early
experience in the USA [291]. However, the combination of
an additional surgical risk and an increased risk of serious in-
fection, especially in the setting of chronic immunosuppres-
sive therapy, lead to a progressive decline of this procedure,
which has been often efﬁciently replaced by rituximab in
series from Japan [273, 275, 292], the USA [278, 279] and
Europe [266]. Finally, even the use of rituximab seems to be
avoidable, as several groups have reported no graft loss and
rate of acute antibody-mediated rejection below 10% by
using plasmapheresis and IVIG alone [274, 279, 280]. Of
note, steroid withdrawal after 1 year in some studies was only
successful in 50% and therefore should be used with great
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How did we translate the evidence into the statement?
The guideline development group acknowledges that ABO in-
compatibility can be a barrier to expansion of living donor
programmes. According to the group, there are two ways out:
one is to avoid ABO incompatibility by organizing a paired ex-
change programme. If successful, and with acceptable delays
on waiting time, such a programme might have beneﬁts over
elimination protocols.
Different protocols for elimination of antibodies have been es-
tablished, always based on a combination of antibody removal
and inhibition of antibody production. As ABO antibodies are
subject to accommodation, excellent outcomes have been ob-
tained with these techniques. However, the pros and cons of
the procedure should be explained carefully and in depth with
the donor and the recipient. As beneﬁts, one can state the
shorter time on dialysis, or even avoidance of dialysis, which is
considered to improve long-term outcome. As a drawback,
one should stress the potential need for higher levels of immu-
nosuppression and the need to continue long-term steroid
therapy.
What do the other guidelines state?
This topic is dealt with by the British Transplant Society,
which mostly agrees with ERBP recommendations [62].
Suggestions for future research
At present, much work remains to be done to establish
which strategy: plasmapheresis and IVIG, speciﬁc immunoab-
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2.8. In previously transplanted patients, what is the effect of
repeated mismatches for HLA antigens on outcome, as com-
pared to avoiding repeated HLA mismatches?
We recommend that repeated HLA mismatches are not
considered a contraindication for transplantation in the
absence of antibodies against those repeated mismatches.
(Ungraded Statement)
We suggest that the presence of antibodies against the
repeated mismatch detectable by other techniques than




Patients with a previously failed graft might form antibodies
against HLA mismatches present in their previous graft.
Taking into account previous mismatches can prolong the
waiting time. When antibodies are present against a previous
mismatch, transplanting a kidney from a donor who also has
that HLA pattern can jeopardize graft survival.
What did we ﬁnd?
The available studies were published in the 1990s and their con-
clusions are difﬁcult to extrapolate to today’s situation. Con-
clusions were conﬂictive regarding class II repeated mismatches
but not class I. Some studies [295–297], but not all [298–302],
have suggested that class II repeated mismatches are detrimental.
The Eurotransplant group has reported that repeat mismatch of
class II had a negative impact on graft survival but only in
patients who had lost their ﬁrst graft in <6 months after trans-
plantation [303]. Others have also found that there was a corre-
lation between the duration of the survival of a ﬁrst graft and
that of the second or further graft [297, 301]. In this previous
era, screening of HLA antibodies was more reliable for class I
than class II. In addition, donor reactivity against a mismatched
antigen was reﬂected by the positivity of the cross-match but
not all centres performed B-cell cross-matches that are supposed
to detect class II immunization. This might explain why class II-
repeated mismatches appeared to be detrimental.
Our actual screening, using more sensitive tests such as
Luminex or ELISA, is more performant than the methods used
previously and is so for any class of HLA antibodies. No study
has been reported to date, on the topic of graft survival in re-
transplantations with repeated mismatches but this question is
linked to the general question of the management of donor-
speciﬁc antibodies before transplantation.
Repeated mismatch could be harmful in patients having a
non-kidney transplant and receiving later a kidney graft. It
cannot be excluded that they have donor-speciﬁc or non-
speciﬁc HLA antibodies that are not detected because they are
trapped in their ﬁrst transplant. One study only addressed this
question. In a small cohort of patients having a heart, lung or
liver transplant and receiving kidney transplantation years
later (respectively, 53 and 22 patients), a repeated mismatch
was present in 31% of patients, but was not associated with
poorer graft survival or lower kidney function at 5 years [304].
How did we translate the evidence into the statement?
A repeated mismatch does not contraindicate transplan-
tation if the patient has not developed immunization against
this antigen. This reactivity was detected by the cross-match in
the past era but our actual screening for identiﬁcation of HLA
antibodies is more sensitive and possibly too sensitive. The
question of the repeated HLA mismatch is part of broader dis-
cussions on the relevance of donor-speciﬁc antibodies de-
tected by the currently available sensitive techniques.
What do the other guidelines state?
No other guideline body produced a statement on this
topic.
Suggestions for future research
Compare outcomes of patients with versus without repeat
mismatch, with outcomes patient and graft survival, acute re-
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CHAPTER 3 . EVALUATION, SELECTION AND
PREPARATION OF DECEASED AND LIVING
KIDNEY DONORS
3.1. When is dual-kidney transplantation preferred over
single-kidney transplantation?
We recommend that before the kidneys of a cadaveric
donor are discarded because they are deemed unsuitable
for single transplantation, transplantation of both kidneys
into one recipient (dual-kidney transplantation) is con-
sidered as an option. (1C)
We suggest that in cadaveric donors where there is un-
certainty about the quality of the kidneys, the decision to
either discard the kidneys, or use them as a dual or a single
transplant, is based on combination of the clinical evalu-
ation and history of the recipient and donor, and when
available, a standardized assessment of a pre-transplant
donor biopsy. (2D)
We recommend that before a kidney from a
paediatric donor is discarded because due to low donor
age it is deemed unsuitable for single transplantation
in an adult recipient, en bloc transplantation is considered.
(1B)
We suggest that the option of using kidneys for en bloc




As a result of the shortage of kidneys for transplantation
and the increasing number of elderly patients on the waiting
list, many organ procurement organizations are increasingly
using kidneys from older donors and from donors with risk
factors adversely affecting kidney function, such as hyperten-
sion or diabetes. This practice carries the risk of using poor-
quality organs which might in turn lead to poor graft
outcome [305–307]. Apart from the surgical problems
related to the presence of severe atherosclerosis in the kidney
allograft vasculature, poor allograft outcome has traditionally
been attributed to an inadequate number of viable nephrons.
This problem also arises when paediatric donors are con-
sidered.
To overcome these, dual-kidney transplantation—in which
both kidneys are transplanted into a single patient—has been
proposed, based on the assumption that the sum of the viable
nephrons in the two kidneys approach the number of one
standard kidney [308, 309]. Such a strategy should expand the
donor pool by recovering kidneys which would otherwise be
discarded. Potential drawbacks of dual transplantation are the
increased risk of perioperative and surgical complications, and
the fact that using two kidney grafts for one
recipient potentially deprives a second person from a scarcely
available resource.
What did we ﬁnd?
We retrieved 32 observational cohort studies comparing dual-
with single- kidney transplant outcomes [308–339]. The studies
differed in the methods of allocating the dual-kidney transplant,
which varied as to the type of donors considered for evalu-
ation, the criteria used for such an evaluation (biopsy, clinical,
both) and the criteria used for decision-making. Only two
studies from the same transplant centre reported explicit criteria
for including the recipients as suitable for dual transplantation
[321, 339]. In most studies, dual transplantations have been per-
formed using kidneys turned down by other transplant centres,
whereas in 10 studies the allocation to dual or single transplan-
tation was based on prospective criteria, which differed among
studies [309, 316, 321–323, 326, 327, 335, 336, 339]. One study
on Organ Procurement and Transplant Network/United
Network for Organ Sharing (UNOS) registry data examined the
adherence to current UNOS Guidelines for dual transplantation
[330]. Pre-transplant donor biopsies were obtained and used as
the sole criteria for allocation of kidneys from marginal donors
in all studies from Italy [309, 321, 323, 326, 327, 339] and pre-
transplant donor biopsies were performed in 75–95% in North
American studies [330, 336], but in a French study, the allo-
cation was based only on the estimated donor’s maximum crea-
tinine clearance [335]. Kidney allograft and patient survival was
evaluated in all studies, whereas kidney function [i.e. serum
creatinine or estimated glomerular ﬁltration rate (eGFR)] and
surgical complications were reported in 10 of the 11 aforemen-
tioned studies. Follow-up ranged between 1 and 3 years and the
number of dual transplants between 21 and 625. No study pro-
spectively evaluated the effects of dual transplantation strategy
on the rate of donor recovery and on the time spent by the reci-
pients on the waiting list.
Concerning paediatric donors, we found 10 observational
cohort studies [312, 313, 319, 324, 325, 329, 333, 334, 337, 338]
comparing en bloc kidney transplantations with single-kidney
transplantation outcomes from standard criteria donors [313,
319, 324, 325, 332, 334, 337, 338], extended criteria donors
[332] and single kidneys [312, 325, 329, 337]. Kidney allograft
and patient survival were evaluated in all studies. In most recent
studies [319, 324, 325, 332, 334, 337] follow-up ranged between
5 and 10 years and the number of en bloc kidney transplan-
tations between 66 and 1162. Surgical complications were com-
pared in four studies [312, 313, 329, 338], the incidence of acute
rejection in three studies [313, 332, 337], the incidence of pro-
teinuria and hypertension in one study [334].
How did we translate the evidence into the statement?
Notwithstanding the less favourable donor characteristics, al-
lograft survival and function of dual transplants approached
that observed in transplants from extended criteria donors
[330, 335, 336] or even that of standard criteria donors [326],
depending on which criteria were used to make the allocation
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kidneys. Unfortunately, no study performed so far provided
sufﬁcient evidence as to the best method to decide between
dual or single transplantation, while ensuring that dual trans-
plantation be restricted to organs that would otherwise be dis-
carded. In fact, no study clearly showed speciﬁc prospective
criteria for allocation yielding single transplants achieving ade-
quate kidney function, dual transplants achieving the same allo-
graft function as the single transplants, and the donor pool
being increased as a result of the implementation of a dual
transplantation policy. However, in some transplant centres, the
strategy of dual transplantation apparently shortened recipient’s
expected time on the waiting list [320, 322, 326]. Overall, dual
transplantation is a relatively safe option. In fact, when dual
transplantation is performed in suitably selected recipients, the
increased risk of perioperative and surgical complications seems
to be only modest, and not associated with an increased mor-
tality [326, 330, 336, 339]. Dual-kidney transplantation can be
carried out by bilateral or unilateral placement of both kidneys.
The latter technique offers the advantage of a single surgical
access and shorter operating times but it is not technically feas-
ible in all recipients [339].
Concerning paediatric donors, en bloc kidney transplantations
have better long-term graft survival and graft function than ex-
panded criteria donor kidneys and standard adult donor
kidneys despite a higher graft loss during the ﬁrst 12 months
post-transplant due to an increased risk of graft thrombosis.
The advantage of en bloc kidney transplantation can be
appreciated even in extreme donor age <5 years for which en
bloc is the transplant technique of choice with respect to the
technique of using single organs for paediatric donors [324,
337]. The risk of early graft loss is inversely proportional to
donor weight and is highest for donor weight below 10 kg
[332]. Donors weighting less than 10 Kg have also the highest
discard rate [325]. Surgical expertise and use of heparin can
profoundly decrease the incidence of early graft loss due to graft
thrombosis in these donors [319]. The incidence of acute rejec-
tion for en bloc kidney transplant is similar to standard kidney
grafts [319, 332, 337]. From a resource perspective, single
kidneys from paediatric donors weighing 10-35 kg used as
singles offer more cumulative graft years than when used en
bloc [332].
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
Establish and evaluate strict donor criteria for single or
dual-kidney transplantation.
Evaluate the impact of a strictly deﬁned dual-kidney pro-
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3.2. Which perfusion solution is best suited for kidney pres-
ervation in recipients of living donation?
Which perfusion solution is best suited for kidney preser-
vation in recipients of deceased kidney donation?
There is insufﬁcient evidence to favour a particular preser-
vation solution for kidneys that carry a low risk of DGF.
(Ungraded Statement)
We recommend not using Eurocollins as a preservation
solution for kidneys that carry a high risk of DGF (long-
projected CIT extended criteria donors). (1B)
Rationale
Why this question?
Cold storage is the most commonly used procedure for kidney
preservation for either living donation or deceased donation
after cardiac death. Several types of preservation solutions and
ﬂuids have been designed according to their extracellular or
intracellular components, viscosity and ability to decrease cell
metabolism during preservation while preventing ischaemic
reperfusion injuries.
What did we ﬁnd?
We found a recent systematic Cochrane review of sufﬁcient
quality on this topic [340].
This review included in total 15 trials, 10 randomized con-
trolled trials (RCTs) and 5 non-RCTs, with a total of 3584
(3004 in RCTs) kidneys, that analysed DGF as primary
outcome. Three RCTs compared University of Wisconsin
(UW) with Euro Collins (EC), three RCTs compared UW with
Celsior, two RCTs and two non-RCTs compared EC with his-
tidine–tryptophan–ketoglutarate (HTK), two RCTs compared
UW with HTK. Overall quality of studies was rather low, with
a JADAD [341] score of three (n = 2), two (n = 6) and one
(n = 2). The deﬁnition of DGF was different in each study.
Euro Collins was associated with a higher risk of DGF than
UW solution in two RCTs (114/343 versus 80/352 and 34/44
versus 32/46) and HTK in two RCTs (18/54 versus 0/34 and
119/277 versus 85/292), with moderate risk of bias. UW was
associated with an equal risk of DGF compared with Celsior in
three RCTs and HTK in two RCTs. These ﬁndings are partly
supported by registry data.
Eleven studies reported comparable graft survival rate at 1 year
for different combinations of perfusion solutions, and one re-
ported worse outcome for EC versus UW (265/300 versus
233/282).
None of the studies was adequately powered to make con-
clusions on primary non-function or on patient survival.
How did we translate the evidence into the statement?
There is a consistent impression that Euro Collins performs
worse when compared with other perfusion solutions with
regard to DGF. There appears to be no evidence for differences
between the other more frequently used perfusions solutions
(UW, HTK, Celsior). As a consequence, the guideline develop-
ment group judged that all solutions can be used when the risk
of DGF is low, e.g. in living donation. When additional risk
factors for DGF are present, e.g. projected long CIT or non-
heart-beating donor, the use of perfusion solutions other than
Euro Collins might be advantageous.?
What do the other guidelines state?
The European Association of Urology states that UW-sol-
ution, HTK-solution and Celsior solution are equally effective
for multi-organ and kidney-only donors [29].
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3.3. Is machine perfusion superior to standard perfusion?
There are conﬂictive data regarding the generalizability of
the beneﬁt of machine perfusion over static cold storage.
Until further evidence emerges, no ﬁrm recommendation
for the use of machine perfusion in preference to cold
storage can be made. (Ungraded Statement)
Rationale
Why this question?
Kidney allografts retrieved from deceased donors may be pre-
served by either static cold storage or machine perfusion.
Machine perfusion is more expensive, and is logistically more
laborious, as it requires staff well trained in the procedure.
What did we ﬁnd?
Until recently, studies examining the potential beneﬁts of
machine perfusion were small and of poor quality. A meta-
analysis of 16 studies with appropriate comparator groups and
sufﬁcient data performed between 1971 and 2001 concluded
that machine perfusion when compared with cold storage was
associated with a small reduction in the risk of DGF (RR: 0.80,
95% CI: 0.67–0.96) [342]. No evidence was found to suggest
that this effect was different for allografts retrieved from heart
beating versus non-heart-beating donors. There was no signiﬁ-
cant effect on 1-year graft survival although even when aggre-
gated, the studies were underpowered. In 2009, Moers et al.
reported the results of a well-designed adequately powered
European multicentre randomized controlled study in which
one kidney from a donor was assigned to machine perfusion
using the LifePort machine (n = 359) with the contralateral
organ assigned to cold storage (n = 359) [343]. However, in 25
donors (4.6%) there were technical difﬁculties (small aortic
patch or multiple arteries) to make connection to the per-
fusion machine, and the surgical teams were permitted to
reverse the randomization. Trained perfusionists were used to
transport and set up the machine perfusion device at the
donor hospital. In 64% of donors, UW ﬂuid was used for vas-
cular ﬂush and preservation, while HTK solution was used in
32%. Machine perfusion signiﬁcantly reduced the risk, dur-
ation and severity of DGF (adjusted OR: 0.57, P = 0.01). The
size of the treatment effect was no different after standard-cri-
teria donation versus expanded-criteria donation. While there
was no difference in DGF or patient survival at 1 year, allograft
survival at 1 year was better in the machine perfusion group
(94 versus 90%; P = 0.04). Because it was considered that an
insufﬁcient number of non-heart-beating donors had been en-
rolled after initial recruitment for subgroup analysis (heart
beating versus non-heart-beating donors), the investigators ex-
tended the study until a total of 82 non-heart-beating kidney
pairs had been randomized. In neither the main data set nor
the extended data set was a signiﬁcant difference observed in
DGF between machine perfusion and cold storage in kidneys
coming from heart beating versus non-heart-beating donors.
However, the same group published a subgroup analysis of
outcome in the 82 non-heart-beating kidney pairs from the ex-
tended data set of the Machine Preservation Trial [344]. In
this paper, the incidence of DGF was 53.7% in machine per-
fusion versus 69.5% in cold storage (P = 0.007) with an ad-
justed OR of 0.43 (95% CI: 0.20–0.89, P = 0.025) for the
probability of developing DGF in machine perfused kidneys
compared with cold storage. There was no difference in 1-year
patient and graft survival. In contrast, Watson et al. also pub-
lished in 2010 the results of a multicentre randomized con-
trolled trial of machine perfusion versus cold storage in non-
heart-beating donor kidneys using only a sequential study
design which stops patient recruitment after there is sufﬁcient
evidence to reject the null hypothesis [345]. After 90 trans-
plants from 45 donor pairs, there was no difference in the inci-
dence of DGF or in any secondary endpoints. In contrast to
Moers’ study, there was standardization of the preservation
ﬂuid (UW) and immunosuppression used. Trained perfusio-
nists were not available and when kidney retrieval occurred
away from the base transplant centre, kidneys randomized to
machine perfusion could ﬁrst undergo a period of cold storage
during transport to the base hospital.
How did we translate the evidence into the statement?
Given these conﬂictive results and in the absence of a pharma-
co-economic evaluation of the cost of employing dedicated
trained perfusionists as part of the retrieval team, no ﬁrm rec-
ommendation can be made regarding the optimum method of
organ preservation until more evidence emerges from further
studies.
What do the other guidelines state?
No other guideline bodies provide a statement on this
topic.
Suggestions for future research
Further adequately powered randomized studies are re-
quired of machine perfusion versus static cold storage in both
heart beating and non-heart-beating donors, and this using
standardized perfusion ﬂuid, with pre-speciﬁed subgroups.
Ideally, these studies should be international and multicentre,
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3.4. Is there a critical cold ischaemia time beyond which a
donated organ should be discarded?
We suggest that CIT is kept as short as possible. (2D)
We recommend keeping CIT below 24 h when trans-
planting kidneys from donors after brain death. (1B)
We recommend keeping CIT <12 h when using kidneys
from donors after cardiac death. (1D)
We recommend that the decision to use donor kidneys




CIT is one of the few potentially modiﬁable donor risk factors
that can have a signiﬁcant inﬂuence on transplant outcome.
However, keeping CIT as short as possible might pose substan-
tial logistical problems. Also, accepting only a short CIT might
lead to loss of otherwise acceptable grafts.
What did we ﬁnd?
Data from the Collaborative Transplant Study (CTS) based on
kidney allograft transplants performed between 1990 and 2004
have shown that increasing CIT up to 18 h has no adverse
effect on graft outcome [346]. For CIT between 19 and 24 h,
the hazard of graft failure increased by 9%, for 25–36 h by 16%
and for >36 h by 30%. Maybe as a result of that, the proportion
of transplants with CIT >36 h decreased from 8.3% between
1990 and 1991 to 0.6% between 2004 and 2005. Compared
with CIT <19 h, 1-year creatinine values were increased sig-
niﬁcantly only for CIT >36 h but not with CIT between 19
and 36 h. There was no evidence that prolonged CIT was more
deleterious for kidneys from elderly donors or from extended-
criteria donors. In comparison, UK registry data have shown
that for recipients of ﬁrst kidney allografts from brain-death
donors, CIT up to 21 h has no effect on transplant failure up
to 5 years of follow-up. However, for every additional hour of
CIT over 21 h, the risk of transplant failure increased by 4%
[347]. For recipients of kidneys from donors after controlled
cardiac death (Maastricht category 3), a CIT >12 h seemed to
be associated with worse graft survival, although results were
not signiﬁcant at the 5% level [348]. For recipients of kidneys
from both cardiac-death and brain-death donors, a CIT >24 h
was associated with an eGFR that on average was ∼5 mL/min/
1.73 m2 lower than in patients with a CIT <12 h [348]. In a
single-centre cohort study of brain death donor kidney trans-
plants from younger donors (<50 years), CIT, when analysed
as a continuous variable, was shown to be an independent risk
factor for graft loss (20% increase for every 5 hours of CIT)
[349]. When analysed as a categorical variable (less than or
longer than 19 hours), a CIT >19 h independently increased
the risk of graft failure by 50%.
CIT is associated with DGF, deﬁned as the need for dialysis in
the ﬁrst week after transplantation. UNOS data reveal that the
incidence of DGF in recipients of kidneys with a CIT of more
than 36 hours was 40% in standard criteria donors and 50% in
extended criteria donors [350]. In a single-centre study of
brain-death donor kidney transplants using a uniform immu-
nosuppression regimen, CIT was also an important risk factor
for the development of DGF. CIT predicted long-term graft
survival in grafts that survived for more than 1 year, and this
independently of DGF [351]. In another more recent single-
centre cohort study, CIT was the single most important inde-
pendent predictor of DGF, which had an incidence of 42%
when the CIT increased to 36 h. CIT was also an independent
risk factor for acute rejection, with each hour of CIT increasing
the risk of acute rejection by 4%. Although CIT was a signiﬁ-
cant independent risk factor for graft loss, this effect was almost
entirely due to its impact on acute rejection. Similarly, the detri-
mental effect of DGF on graft survival was explained by an in-
creased incidence of acute rejection [352].
How did we translate the evidence into the statement?
CIT is an important modiﬁable risk factor that can inﬂuence
outcome. Therefore, every effort should be made to keep CIT
to as short as possible. Based on the evidence above, the ERBP
group recommends that when transplanting kidneys after
brain death, the CIT should be kept below 24 h. Because non-
heart-beating donor kidneys are subjected to longer warm
ischaemia and have a higher incidence of delayed function,
minimizing CIT is even more important in this setting. Based
on observational studies, we recommend that when trans-
planting kidneys after controlled circulatory death (Maastricht
category 3) CIT is kept <12 h. There are few data reporting the
outcome of kidney transplants with very long CIT, i.e. >36 h.
However, it was the opinion of the group that the high inci-
dence of DGF, the worse outcome with increasing CIT and the
increased risk of acute rejection means that these kidneys
should not usually be used, unless under exceptional circum-
stances and after full discussion of the risks and beneﬁts with
the potential recipient.
What do the other guidelines state?
Like ERBP, the European Association of Urology rec-
ommends to keep CIT as short as possible [29]. No other
guideline body provides any indication on which maximal
CIT is acceptable.
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3.5. On which criteria should we select living kidney donors
to optimize the risk–beneﬁt ratio of their donation?
General remarks
We recommend encouraging living kidney donors to ex-
ercise on a regular basis and when relevant, to lose weight
and stop smoking. (1C)
We recommend that the individual risk of donation
should be carefully discussed with the donor, taking into
account the situation of both donor and recipient. Ideally,
this should be done using standardized check lists to
ensure all items are discussed. (Ungraded Statement)
We suggest that the donor be evaluated by an indepen-
dent physician who is not part of the transplant team and
is not involved in the daily care of the recipient, and when
possible, by a psychologist. (Ungraded Statement)
We recommend that the process of donation is stopped
should any doubt on donor safety arise, especially in
younger donors, or when the beneﬁt for the recipient is
limited. (Ungraded Statement)
We recommend that the simultaneous presence of more
than one risk factor (hypertension, obesity, proteinuria, im-
paired glucose tolerance, haematuria) precludes donation.
(Ungraded Statement)
Hypertension
We recommend considering potential donors with a
blood pressure <140/90 mmHg on at least three occasions
without antihypertensive medication, as normotensive. (1C)
We suggest measuring ambulatory blood pressure in
potential donors who have ofﬁce hypertension (blood
pressure ≥140/90 mmHg) or who are taking pharmaco-
logical treatment for hypertension. (2C)
We suggest well-controlled primary hypertension, as as-
sessed by ambulatory blood pressure <130/85 mmHg,
under treatment with maximum two anti-hypertensive
drugs (diuretics included) is not considered a contraindica-
tion to living kidney donation. (2C)
We recommend discouraging hypertensive donors with
evidence of target organ damage such as left ventricular hy-
pertrophy, hypertensive retinopathy and micro-albuminuria.
(1C)
We suggest that these potential donors could be re-eval-
uated for disappearance of this target organ damage after
appropriate treatment. (2D)
Obesity
We suggest a BMI >35 kg/m2 is a contraindication to
donation. (2C)
We recommend counselling obese and overweight
donors for weight loss before and after donation. (Ungraded
statement)
Impaired glucose tolerance
We recommend diabetes mellitus is a contraindication
to donation, other than in exceptional circumstances. (1D)
We suggest impaired glucose tolerance is not an absol-
ute contraindication to donation. (2C)
Proteinuria
We recommend quantifying urinary protein excretion
in all potential living donors. (1C)
We recommend overt proteinuria is a contraindication for
living donation [24-h total protein >300 mg or spot urinary
albumin to creatinine (mg/g) ratio >300 (>30 mg/mmol)].
(1C)
We recommend further evaluating potential living
donors with persistent (more than three measurements
with 3 months interval) proteinuria <300 mg/24 h by the
quantiﬁcation of micro-albuminuria to assess their risk of
living donation. (Ungraded statement)
We suggest considering persistent (more than three mea-
surements with 3 months interval) micro-albuminuria (30–
300 mg/24 h) a high risk for donation. (Ungraded statement)
Haematuria
We recommend considering persistent haematuria of
glomerular origin as a contraindication to living donation,
because it may indicate kidney disease in the donor. (1B)
However, we acknowledge thin basement membrane
disease might be an exception. (Ungraded statement)
Old age
We recommend that old age in itself is not a contraindi-
cation to donation. (1B)
Rationale
Why this question?
Owing to the ever increasing waiting times required to receive
a kidney transplant from deceased donors, more and more
reliance is currently being put on living-donor kidney trans-
plantation as the treatment of choice for end-stage kidney
disease. To resolve pressure on the cadaveric waiting list, sub-
jects who in the past were deemed unsuitable for living
donation, nowadays are increasingly being considered as suit-
able candidates, so that donors with medical abnormalities
form a signiﬁcant proportion of the living donors [353].
What exactly the long-term effects of donation are in this
population remains uncertain. In particular, it still remains
to be answered whether or not donors with relevant risk
factors such as hypertension, obesity, old age, impaired
glucose tolerance, proteinuria or haematuria, have safe
outcomes in the long term. The impact of borderline-
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What did we ﬁnd?
Experience gained with unilateral nephrectomy performed on
servicemen, who lost a kidney due to trauma during World
War II, showed that the long-term risks inherent to this pro-
cedure when compared with non-nephrectomized servicemen
are minimal [354]. This ﬁnding was later conﬁrmed by a com-
parison of donors with non-donating siblings [355]. More re-
cently, several studies showed excellent long-term outcomes in
donors compared with an age-matched general population
[356]. However, these studies were limited to highly selected do-
nors, who were young, white, and generally free from relevant
risk factors, in contrast with current donors who are often
obese, hypertensive and increasingly older [357]. It is likely that
the risk of living donation in individuals with medical disorders
varies with race, since it has been shown that after kidney
donation black donors, when compared with white donors,
have an increased risk of developing hypertension, diabetes and
chronic kidney disease [358]. Segev et al. examined donor survi-
val over a median of ∼6 years follow-up in a cohort of over 80
000 donors from 1994 to 2009 [545 with hypertension and
4473 with BMI≥ 30 kg/m2], and compared it with a matched
cohort of ∼9000 healthy subjects selected from NHANES III
[359]. This is the only large study comparing living donors with
healthy controls rather than with the general population. More-
over, at variance with previous studies, the population included
a signiﬁcant proportion of black (13%) and Hispanic (12%)
individuals. On overall, living donation was not associated with
an increased risk of death compared with a healthy matched
cohort. However, being retrospective, this study could not fully
control for all potential confounding factors. Moreover, there
were too few events to provide reliable estimates for each risk
subgroup of living donors.
Few multicentre cohort studies have been carried out choosing
appropriate control groups, adjusting for all relevant con-
founding factors, using standardized deﬁnitions of donor risk
factors and outcomes, and providing sufﬁcient length and
completeness of patient follow-up. Moreover, no study was de-
signed to assess the effect of each donor risk factor in the
context of the other risk factors which may have an additive
effect in increasing the risk of living donation and, ﬁnally, no
study examined the long-term outcome of young donors with
risk factors associated with future development of hyperten-
sion or diabetes.
Therefore, the recommendation is mostly based on the natural
history of the medical abnormalities, on common sense, and
consensus between the guideline development group
members.
Hypertension
A systematic review of the literature until 2008 found six
studies involving 115 donors with pre-existent hypertension,
and 621 controls from three studies [360]. Overall, quality of
the studies was low, with 3/6 not providing a clear deﬁnition of
hypertension, and only one stating that blood pressure was
measured by a professional. Change in blood pressure after
donation was quantiﬁed in only one study, where blood
pressure did not increase 1 year after donation. One study
assessed change in the mean arterial blood pressure after
donation, which decreased more often in hypertensive donors.
In the study of Segev et al., out of the ∼30 000 donors with
blood pressure data available, 545 (1.8%) had pre-existent hy-
pertension. Hypertension was associated with an increased risk
of death in living donors (36.7, 95% CI: 4.4–132.6/10 000
donations versus 1.3, 95% CI: 0.4–3.4/10 000 donations) [359].
However, these risk estimates were based on only two deaths in
the cohort of hypertensive patients. Textor et al. examined the
short term, mainly 1-year, change in arterial blood pressure,
kidney function and proteinuria of 148 donors with pre-existent
hypertension, and compared it with normotensive donors
[361]. After 282 days, normotensive donors had no change in
awake ambulatory blood pressure monitoring measurements
(before 121/75 mmHg versus after 120/75 mmHg), whereas
blood pressure in hypertensive donors fell with both non-
pharmacological and drug therapy (before 142/85 mmHg to
after 132/80 mmHg, P < 0.01). After correction for age, no inde-
pendent effect of hypertension before donation was evident for
predicting GFR after nephrectomy. Urine protein including
micro-albuminuria did not change after donor nephrectomy. It
is worth noting that in the Textor study only a minority of ‘hy-
pertensive’ patients were taking anti-hypertensive medications,
despite blood pressures >140/90 mmHg in 96%, and awake
ambulatory blood pressure monitoring >135/85 mmHg in 75%
of the donors [361]. Tent et al. compared 47 hypertensive
donors to 94 control donors [362]. Pre- and early post-donation
systolic and mean arterial blood pressures were signiﬁcantly
higher in hypertensive donors. Control donors showed a rise in
diastolic blood pressure after donation, and thus the pre-
donation difference was lost post-donation. Both at 1 year (29
hypertensive donors, 58 controls) and 5 years after donation (13
hypertensive donors and 26 controls), blood pressure was
similar between the groups, and kidney function was similar at
all time-points. Both studies involved mainly white donors,
whereas African-American living donors were reported to have
an increased risk of developing hypertension and chronic
kidney disease [358].
Obesity
A meta-analysis on the effect of obesity on the risk of perio-
perative complications after living donation compared 294
donors with BMI >30 kg/m2 to 624 non-obese controls
(average BMI 34 kg/m2 and 24 kg/m2, respectively) [360]. In
the obese donors, the operative time was on average 20 min
longer (95% CI: 14–26 min), and length of hospital stay was
0.1 days longer (95% CI: 0.0–0.3 days). Compared with
donors having a BMI <25 kg/m2, the crude risk for post-oper-
ative wound complications (infection, seroma, hernia) in-
creased from 2 to 4% for donors with a BMI = 25–30 kg/m2
and ∼9% in donors with BMI ≥30 kg/m2 [363]. In this study,
no differences in micro-albuminuria post-donation were ob-
served with increasing BMI. After adjusting for male sex,
anomalies of kidney vessels, right versus left kidney and la-
paroscopic versus open surgery, a BMI >30 kg/m2 was associ-
ated with an odds ratio of 1.76 (95% CI: 0.66–4.70) for major
perioperative complications (45 events in total) in the Norwe-
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of 1006 donors (524 and 85 donors with pre-donation BMI
>25 kg/m2 and BMI >30 kg/m2, respectively) [364]. In this
registry, post-operative wound infection (event number = 37)
was associated with BMI >25 kg/m2. No study has explicitly
examined whether the risk of perioperative complications in
obese donors is different according to the type of surgical pro-
cedure (laparoscopic donor nephrectomy versus open
surgery).
Segev et al. compared ∼4400 donors with BMI ≥30 kg/m2
with 15 300 donors with BMI <30 kg/m2, ﬁnding that obesity
was not associated with increased mortality among living
donors in short-to-medium term [359]. In the study of
Ibrahim et al., for each unit of BMI there was a 12% increase
in the odds of post-donation eGFR <60 mL/min/1.73 m2, and
post-donation hypertension requiring medications [356].
However, the ﬁnding of an association between high BMI
(>30 kg/m2) and the risk of a signiﬁcant post-donation GFR
decline was not conﬁrmed by two other studies [353, 365].
African-American living donors with a BMI >35 kg/m2 might
be at particularly high risk of developing a signiﬁcant kidney
function decline post-donation [366].
It is worth mentioning that donors with high BMI have
often a further increase in weight following donation [367].
No study estimated the absolute additional long-term risk in
the young obese donors when compared with non-donor
counterparts. Moreover, all these data being observational, it is
unclear whether obese donors were selected among those who
were otherwise healthy, i.e. with no additional risk factors
such as, e.g., hypertension or diabetes. Finally, it must be
stressed that in the same studies the proportion of very obese
subjects (>35 kg/m2) was generally low. Therefore current
available evidence regarding the safety of living donation in
such donors is scarce.
Impaired Glucose Tolerance
Only one study, carried out in Japan, examined the effect of
impaired glucose tolerance on living donor outcome [368].
This study compared donors having either impaired glucose
tolerance (n = 44) or true diabetes mellitus (n = 27), with 373
normo-glycaemic donors. However, among the diabetic
donors only ﬁve were receiving anti-diabetic treatment, whi-
le the other glucose-intolerant donors had been classiﬁed as
diabetics only on the basis of the oral glucose tolerance test
(OGTT) performed at the time of evaluation. Donors showing
micro-albuminuria, haemoglobin A1c ≥6.5%, or diabetic
complications were not included because deemed unsuitable
for kidney donation. The follow-up was ∼9 years on average.
Perioperative complications, kidney function and patient sur-
vival did not differ according to the presence or not of pre-
transplant glucose intolerance. One of the ﬁve diabetic donors
already on treatment at the time of transplant was lost to
follow-up, another donor showed an increase in serum creati-
nine from the pre-transplant value of 1.04 to 1.44 mg/dL 27
months after transplantation.
Proteinuria
Only one study examined the role of proteinuria on donor
outcome by comparing the changes in kidney function, arter-
ial blood pressure and proteinuria occurring 1 year after
donation in eight subjects having abnormal proteinuria, and
in 75 control donors [369]. The study was performed between
1988 and 1998, therefore the deﬁnition of abnormal proteinur-
ia was not adherent to the current standard of today (urinary
albumin/creatinine >10 mg/mmol or protein/creatinine >0.02
g/mmol). Anyhow, the borderline-high levels of proteinuria
were not associated with any adverse effect on donor kidney
function or blood pressure.
Haematuria
Living donations from individuals having haematuria due
to proven glomerular kidney diseases have been reported:
three had Immunoglobulin A (IgA) nephropathy [370], two
thin basement membrane disease [371] and six were affected
mothers donating the kidney to sons suffering from Alport
syndrome [372]. Length of follow-up ranged between 1 and 10
years. In this small case series, at least one of the donors with
IgA nephropathy, and two of the mothers of patients with
Alport syndrome developed hypertension, proteinuria and sig-
niﬁcant kidney function decline beyond 1 year after donation.
There is only one study, performed in Japan, which estimated
the increased risk associated with isolated renal haematuria
(deﬁned as more than ﬁve dysmorphic erythrocytes in urine
per high power ﬁeld) in living donors who were not evaluated
by kidney biopsy [373]. In this study, 22 donors with pre-
transplant renal haematuria and 220 haematuria-free control
donors were retrospectively followed-up for an average of
∼2 years. The study population included 43 subjects with
family history of IgA nephropathy or Alport syndrome.
A family history of IgA nephropathy increased the risk of
haematuria after donation. In 70% of the donors with renal
haematuria before donation, haematuria showed a persistent
pattern (i.e. conﬁrmed after >3 month interval). Almost
invariably, donors having persistent haematuria before
donation continued showing this urinary abnormality after
donation. Persistent renal haematuria post-donation was
associated with a declining GFR post-donation (±2 mL/min/
year). For the case of haematuria associated with the relatively
benign condition of thin basement membrane disease, there
are no data in the setting of living donation.
Old Age
Older living donors, deﬁned in the various studies as aged
≥60 or ≥65 years, apparently do not have an increased risk of
death after donation compared with the matched healthy popu-
lation of the same age [359]. In fact, older age is not associated
with a signiﬁcant increase in perioperative complications such
as blood loss, intraoperative incidents or wound infections, nor
with an increased length of hospital stay [360], although an in-
creased risk of cardiac and pulmonary complications in donors
over 60 years has been reported in one study [374].
A meta-analysis on the effect of older age on kidney func-
tion after donation [360], including 181 older donors and 666
younger donors, did not ﬁnd a negative impact of older donor
age on kidney function post-donation after a median follow-
up of 2 years. On the other hand, Ibrahim [356] reported that
older age is a determinant of low (i.e. <60 mL/min per 1.73 m2)
measured GFR post-donation after adjusting for creatinine
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measured in a random sample of 7% of the study population,
was not available at baseline. Moreover, the ﬁnding that older
age was associated with an increased risk of renal function
decline after donation was not conﬁrmed by a subsequent
observation in another transplant centre [375]. Long-term
changes in blood pressure and proteinuria in older donors
have not been extensively investigated. Two studies comparing
older with younger donors [369, 376] reported inconsistent
ﬁndings on blood pressure. More recently, Ibrahim and col-
leagues found that older age is a determinant of hypertension
requiring medication after donation [356]. The analysis was
adjusted for pre-donation systolic and diastolic blood pressure
but not for the use of anti-hypertensive medication before
donation. One study did not ﬁnd any effect of age at donation
on the albumin:creatinine ratio after 1-year follow-up, a
ﬁnding conﬁrmed by Ibrahim [369].
It is worth noting however, that in all the above-mentioned
studies it is unclear whether the cohorts of older living donors
had a lower prevalence of additional pre-donation risk factors
compared with younger donors, since no study fully adjusted
for all the potential relevant pre-donation confounding
factors. Therefore, selection bias cannot be excluded.
How did we translate the evidence into the statement?
As presence of comorbidity often precludes donation, the evi-
dence on the impact of these comorbidities on outcome after
donation is scarce. Whereas for the presence of single risk
factors, some low-quality evidence can be found, the lack of
evidence on the impact of a combination of risk factors for
donation does not allow exactly quantifying the additional risk
for an individual donor with a speciﬁed set of comorbidities.
The guideline development group judged that, as a general
rule, persistent the presence of more than one risk factor
should preclude donation in most, if not all, cases.
Some risk factors (blood pressure, obesity, nicotine abuse) can
be modiﬁed, and effort should be made by the transplant team
to obtain this modiﬁcation before the donation.
In the absence of comorbidities, a blood pressure repeatedly
<140/90 mmHg should be considered as ‘normotension’, as it
is unlikely that this person would have higher blood pressures
under more normal conditions.
If blood pressures >140/90 mmHg are recorded, ‘white coat’
or ofﬁce hypertension should be excluded by ambulatory
blood pressure recording.
Patients who have hypertension that is well controlled by
medication (<130/85 mmHg on ambulatory blood pressure
monitoring with two different drugs at maximal dose) can be
considered normotensive. There is some suggestion that, after
donation, blood pressure decreases in these patients, maybe
because compliance increases.
Although the evidence for the negative impact of hypertension
in the setting of living donation is scarce, the strong associ-
ation between hypertension and negative cardiovascular
outcome in the general population is so overwhelming that the
guideline development group judged that it can most likely be
translated to the peculiar situation of living donation. Potential
donors should be informed that a negative effect is even more
likely if they already have end-organ damage at the moment of
evaluation (proteinuria, left ventricular hypertrophy, hyper-
tensive retinopathy). As treatment of hypertension in some of
these potential donors might have been suboptimal until the
moment of evaluation for living donation, a re-evaluation after
adequate treatment has been installed should be planned if the
wish to donate persists.
Obesity as deﬁned by BMI is associated with a relative increase
in peri- and post-operative complications: mainly wound in-
fection and wound healing. However, these problems appear
to be relatively minor in relation to the potential gain for the
recipient, especially as long as BMI is not >35 kg/m2. Atten-
tion should be given to presence of other risk factors,
especially glucose intolerance, micro-albuminuria and hyper-
tension. It should also be taken into account that a deﬁnition
of obesity based on BMI does not differentiate between central
obesity (fat) and high muscle mass, whereas these two con-
ditions might be distinct in terms of outcome of living
donation.
Persistent micro-albuminuria is a marker of kidney disease,
and/or enhanced cardiovascular risk. Occasional albuminuria
can be present even in normal persons, e.g. after exercise.
Therefore, the diagnosis ‘micro-albuminuria’ should only be
made when several samples with some months interval have
been positive.
Presence of haematuria is a sign of either glomerular of urolo-
gical disease, and should be further explored. The ERBP guide-
line development group judges that haematuria precludes
living donation. Haematuria can be a sign of thin basement
membrane disease, and it is unclear whether living donation is
safe (both for the donor and the recipient) or not in this con-
dition.
Old age by itself should not be considered a contraindication
to donation. Indeed, older donors do have a lower expected
life span, and ‘kidney survival’ might be less an issue in these
circumstances. Older patients should however be screened for
the presence of other comorbidities, which could exacerbate
after nephrectomy or jeopardize the remaining kidney (hyper-
tension, proteinuria, diabetes).
What do the other guidelines state?
Hypertension
KHA-CARI provides suggestions for clinical care based on
weak evidence which not only suggests 24-h ambulatory blood
pressure measurement but also home blood pressure measure-
ments for exclusion of white coat hypertension [377]. KHA-
CARI states a different threshold for systolic blood pressure as-
sessed by 24 h ambulatory blood pressure measurement of
<135 mmHg as target for potential kidney donors. KHA-
CARI suggests excluding hypertensive donors with end-organ
damage, but also with other cardiovascular risk factors. They
do not state anything on re-evaluating potential donors with
target organ damage after appropriate treatment for donation.
The Amsterdam Forum on the Care of the live kidney donor
considers potential donors with a blood pressure >140/90










 at Bibliotheque Fac de M






generally unacceptable [378]. They suggest that under certain
conditions (>50 years of age, GFR >80 mL/min and urinary
albumin excretion <30 mg/day), such donors can be accepted
for donation, after their blood pressure has been controlled.
A recommendation on hypertensive donors with target organ
damage is not provided by the Amsterdam Forum. Rec-
ommendations of the UK Renal Association and the British
Transplant Society on this topic are in line with ERBP [28, 62].
Obesity
KHA-CARI provides suggestions for clinical care based
on weak evidence and suggests a stricter threshold of BMI
>30 kg/m2 as relative contraindication to donation [379].
They suggest using both the BMI and the waist circumfer-
ence as tools for clinical assessment of risk of donation.
They suggest taking into account eventual additional risk
factors to obesity for chronic kidney disease, such as im-
paired glucose tolerance, hypertension or proteinuria, which
are, according to KHA-CARI, contraindications to donation
in obese patients.
The Amsterdam Forum on the Care for the live kidney
donor endorses guidelines similar to ERBP, but in addition
stresses that the contraindication to donation is stronger if
additional risk factors are also present [378].
The UK Renal Association and British Transplant Society
endorse similar recommendations as ERBP in regard of en-
couraging the obese donor to lose weight prior to donation and
maintain an ideal weight after donation [28, 62]. Like ERBP the
UK Renal Association and the British Transplant Society simi-
larly recommend to discourage potential donors with a BMI
>35 kg/m2 from donation. For the UK Renal Association, the
presence of additional comorbidities in patients with ‘moderate
obesity’ (BMI 30–35 kg/m2) should also be a relative contraindi-
cation for donation, and these patients should be counselled
about the potential risks of donation.
Impaired Glucose Tolerance
KHA-CARI suggests how to assess blood glucose levels in
donors in a very detailed way. In contrast to ERBP, they do
not only consider manifest diabetes mellitus, but also im-
paired glucose tolerance and a history of gestational diabetes
an absolute contraindication for living kidney donation, ac-
knowledging the evidence base is weak [380]. The Amsterdam
Forum on the Care of the live kidney donor suggests that
potential donors with a history of diabetes, an impaired
fasting glucose or OGTT should not donate [378]. Unlike
ERBP, the UK Renal Association and British Transplant
Society do not consider diabetics as unsuitable for live kidney
donation under speciﬁc conditions, and after careful assess-
ment of the presence of other risk factors [28, 62]. They do
not suggest using diabetic living donors to be routine practice,
but rather a possibility in selected, well-informed patients.
Proteinuria
KHA-CARI provides suggestions for clinical care based on
weak evidence which are in agreement with ERBP in regard of
considering micro-albuminuria and overt proteinuria of >300
mg/day a contraindication [381]. Based on opinion, KHA-
CARI suggests that kidney biopsy may help in assessing the
donor’s risk in the case of minor proteinuria. KHA-CARI also
recommends that donors should have their proteinuria
checked annually after donation. The Amsterdam Forum on
the Care of the live kidney donor agrees on considering protei-
nuria of >300 mg/day a contraindication for live kidney
donation but does not provide a recommendation on micro-
albuminuria [378]. The UK Renal Association and British
Transplant Society endorse similar recommendations as the
Amsterdam forum, except that in regard of the absence of
clear data on the role of micro-albuminuria, they suggest a
careful evaluation and counselling of these patients on the
potential risks, rather than accepting it as a plain contraindica-
tion for donation [28, 62].
Haematuria
KHA-CARI suggests excluding urological and kidney
disease before donation, based on weak evidence. They indi-
cate that recommendations on thin basement membrane
disease cannot be made [382]. Recommendations from the
UK Renal Association and British Transplant Society as well
as the Amsterdam Forum on the Care of the live kidney donor
are in line with ERBP [28, 62, 378].
Old Age
The UK Renal Association and British Transplant Society
agree that old age itself is no contraindication for living kidney
donation [28, 62].
Suggestions for further research
Decision analysis techniques should be used to
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3.6. What lower level of kidney function precludes living
donation?
We recommend that all potential living kidney donors have
their GFR assessed. (1C)
We recommend that in cases where more exact knowl-
edge on GFR is needed or where is doubt regarding the
accuracy of GFR from estimation methods, a direct
measurement of GFR is undertaken by exogenous clear-
ance methods. (Ungraded Statement)
We recommend that all potential donors should have a
predicted GFR that is projected to remain above a satisfac-
tory level after donation within the life-time of the donor
as indicated in ﬁgure 3. (Ungraded Statement)
Rationale
Why this question?
Assessment of a potential living donor’s kidney function is es-
sential to ensure that they will have sufﬁcient residual kidney
function after donation to live out their life without any
adverse consequences related to their reduced renal mass.
A secondary consideration is ensuring that the trans-
planted kidney will provide sufﬁcient function for the
intended recipient.
What did we ﬁnd?
An accurate assessment of the GFR should be undertaken in
all potential kidney donors. Although there is currently no evi-
dence that favours the use of a directly measured GFR (iotha-
lamate, EDTA, DTPA or iohexol) over an estimated GFR in
donor assessment, some guidelines organizations make this
recommendation, given the imprecision of the estimated
methods [62].
Much of the evidence relating to kidney function in living
donors comes from underpowered, retrospective cohort
studies, with poor follow-up and without suitable matched
controls [383]. However, the long-term outcome of a reason-
ably sized cohort of living donors (2199 out of a total of 3404
who were still alive and consented to provide data) carefully
assessed at a single US centre from 1963 to 2007 is widely
cited [356]. All donors had a GFR >80 mL/min/1.73 m2 at the
time of donation. The survival of kidney donors was similar to
that of controls in the general population, who were matched
for age, sex and race or ethnic group. End-stage kidney disease
that necessitated dialysis or transplantation developed in 11
donors, a incidence of 180 cases per million persons per year
compared with an incidence of 268 per million per year in the
general population. A subset of 255 donors randomly selected
but stratiﬁed by sex and years since donation underwent
measurement of their GFR, urinary albumin to creatinine ratio
and quality of life assessment. At a mean of 12.2 ± 9.2 years
after donation, 86% of this subgroup had a GFR ≥60 mL/min/
1.73 m2 (none had a GFR <30 mL/min/1.73 m2), 32% had hy-
pertension and 13% had albuminuria. Older age and higher
body mass index, but not a longer time since donation, were
associated with both a GFR that was <60 mL/min/1.73 m2 and
hypertension. A longer time since donation was independently
associated with albuminuria. Most donors had quality-of-life
scores that were better than those in the general population
and the prevalence of co-morbidities was similar to that of
controls. However, the mean age of the subset at the time of
donation was 41 years, 99% were white and 60% were women.
After the age of 40, kidney function declines at a mean speed
of∼ 0.9 mL/min/1.73 m2/year [384]. These data have been
used for deﬁning minimal age-dependent GFRs in living
donors such that the GFR of the remaining kidney will be
>37.5 mL/min/1.73 m2 at the age of 80 [62].
One needs to be careful when extrapolating these data to
potential donors from different racial and ethnic groups. In a
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large US registry study, the rate of established kidney failure
occurring in living kidney donors while being low overall was
nearly ﬁve times higher for black donors than for white
donors (and two times higher for males than for females)
[385]. Although the authors note that these ethnic differences
are similar to those observed in the general population, the
absence of prospective measures of kidney function in black
donors after donation with adequate follow-up and appropri-
ately matched controls introduces uncertainty which should
be shared with the potential donor during their pre-donation
assessment. The growing willingness to consider and accept
donors with isolated medical problems such as hypertension,
glucose intolerance, obesity etc., should, until appropriate data
become available, be avoided in this ethnic group.
How did we translate the evidence into the statement?
We recommend that all potential living kidney donors should
have their GFR assessed and that where there is doubt regard-
ing the accuracy of GFR from estimated methods, a direct
measurement of GFR should be undertaken by exogenous
clearance methods. We recommend that all potential donors
should have a predicted GFR that will remain above a satisfac-
tory level within their life-time. We suggest using ﬁgure 3 as a
reference to predict evolution of GFR after donation. The
upper line in this graph represents the lower limit of normal at
different ages, as determined in 428 living donors (courtesy to
British Transplant Society and UK Renal Association) [386].
The lower line depicts the lower boundary of GFR before
donation for different ages that will still lead to an acceptable
GFR at 80 years. For potential living donors >50 years old, a
measured GFR >80 mL/min per 1.73 m2 will provide sufﬁcient
kidney function not to cause ill health in the future.
What do the other guidelines state? KHA-CARI provides
suggestions for clinical care in regard of donor kidney function
but no recommendations based on high level evidence [383].
KHA-CARI suggests that serum creatinine and estimated
clearances can be used, as there is no evidence in living
donation that more expensive and laborious techniques such
as CrEDTA, provide any additional beneﬁt. KHA-CARI does
not suggest making an age-dependent cut-off for accepting
donors. The Amsterdam Forum on the Care of the live
kidney donor recommendations are in line with ERBP [378].
They also state an age-dependent estimated GFR cut-off for
not accepting a live kidney donor. The UK Renal Association
and British Transplant Society recommend GFR measure-
ment using a reference GFR procedure, e.g. 51Cr EDTA and
discourage using eGFR methods, as they state these are not
validated in the ﬁeld of living donation [28, 62]. Concerning
a cut-off for the minimum acceptable GFR in a potential
donor the UK Renal Association and BTS recommend a pre-
dicted GFR of at least 37.5 mL/min/1.73 m2 at the age of 80
after donation.
Suggestions for future research
Prospective studies examining long-term kidney function,
cardiovascular disease or surrogate markers and complications
of chronic kidney disease in older donors with appropriately
matched controls.
Prospective studies examining the relationship between
pre-donation GFR and long-term kidney function, cardiovas-
cular disease or surrogate markers, and complications of
chronic kidney disease with appropriately matched controls in
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3.7. What are the risks of pregnancy in a woman with a
single kidney after living kidney donation?
We recommend informing women of childbearing age that
as they are a selected from a very healthy subpopulation,
donation increases their individual risk from below that of




In women of child bearing age, the wish for future pregnancy
can be an obstacle for living donation. Women with a single
kidney might be at enhanced risk during pregnancy, itself a
cause of hyperﬁltration, proteinuria and hypertension.
What did we ﬁnd?
Buszta et al. reported a retrospective, single-centre experience
of 39 pregnancies in 23 patients after living kidney donation
[387]. Transient proteinuria >300 mg on dipstick was seen in
two patients in the third trimester, and trace proteinuria in
seven pregnancies. In a larger single-centre retrospective
cohort, Ibrahim et al. reported 1085 women with in total 3213
pregnancies and 504 women without pregnancy [388]. Foetal
and maternal outcomes in post-donation pregnancies were
comparable with published rates in the general population.
Post-donation versus pre-donation pregnancies were associ-
ated with a lower likelihood of full-term deliveries (73.7 versus
84.6%, P = 0.0004), a higher likelihood of foetal loss (19.2%
versus 11.3%, P < 0.0001) and were also associated with a
higher risk of gestational diabetes (2.7 versus 0.7%,
P = 0.0001), gestational hypertension (5.7 versus 0.6%,
P < 0.0001), proteinuria (4.3 versus 1.1%, P < 0.0001) and pre-
eclampsia (5.5 versus 0.8%, P < 0.0001). In a separate analysis
including women who had both pre- and post-donation preg-
nancies, similar results were observed.
Reisater et al. identiﬁed a cohort of 326 donors, with 726 preg-
nancies, of which 106 after donation [389]. In univariate
analysis, no differences were observed in the occurrence of
pre-eclampsia (P = 0.22), but after adjustment, it was more
common in pregnancies after than before donation (6/106
versus 16/620, P = 0.026). The occurrence of stillbirths was
higher after versus before donation (3/106 versus 7/620),
where it was equal to controls from the general population. No
differences were observed in the occurrence of adverse preg-
nancy outcome in kidney donors and in the general popu-
lation in unadjusted analysis.
Wrenshall et al. reported 45 pregnancies in 33 women who
donated a kidney [390]. Complications incurred during ges-
tation were grossly comparable with those reported in the
general population (miscarriage 13.3%, pre-eclampsia 4.4%, ge-
stational hypertension 4.4%, proteinuria 4.4% and tubal preg-
nancy 2.2%). Foetal abnormalities, persistent hypertension,
proteinuria or changes in kidney function were not noted. Infer-
tility was a problem in 8.3% (3/36) of the respondents, com-
pared with a worldwide incidence of 16.7%.
How did we translate the evidence into the statement?
There is no evidence for increased problems to conceive for
women post-donation, at least when compared with the
general population.
There is no evidence that nephrectomy results in serious
adverse events during pregnancy. In general, the risk of preg-
nancy is comparable with that of the general population.
However, it should be noted (and explained to the potential
living donor), that the results of the general population
include outcomes of all types of women, some of which with
known or unknown comorbidities, such as diabetes, hyperten-
sion, underlying genetic or systemic disease. On the other
hand, accepted candidates for living donation are highly se-
lected, and generally have no comorbidity. Therefore in prin-
ciple, there risk should be much lower than in the general
population.
What do the other guidelines state?
KHA-CARI states that there is no evidence of increased
pregnancy complications after previous donation when com-
pared with the general population. However, they do not draw
attention to the fact that live donors are a selected subpopu-
lation that should in principle have a lower risk than the
general population [391].
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3.8. What is the best surgical approach for living donor
nephrectomy for the donor? What is the best surgical
approach for living donor nephrectomy for the recipient?
For living donor nephrectomy, we suggest either a mini-
mally invasive or laparoscopic approach rather than a ﬂank
subcostal retroperitoneal one. The choice between minimal
invasive and laparoscopic procedure should be based on
the local expertise. (2C)
Rationale
Why this question?
Different surgical techniques to harvest a kidney from a living
donor have been described. It is unclear whether one method
has advantages over the other with regard to donor safety,
donor comfort or graft function and survival. The major disin-
centive for relatives and partners contemplating kidney
donation is the pain, scarring and morbidity associated with
the large incision of a conventional surgical approach [392,
393]. The conventional methods of donor nephrectomy have
recently been challenged by potentially less-invasive oper-
ations using laparoscopic techniques.
What did we ﬁnd?
Different surgical techniques have been described to harvest
kidneys from living donors. In the classic transperitoneal ap-
proach, the kidney is harvested through a midline or through a
left or right subcostal incision, whereby the peritoneum is
opened. The sub or supra costal approach can also be per-
formed without opening the peritoneal space. In the dorsal
lumbar technique, an incision is performed underneath the
12th rib, and the 12th rib is resected. As an alternative, the
incision goes above the 12th rib; in both cases, the approach is
extraperitoneal, and care should be taken not to open the
pleural space. Harvesting of the kidney can also be done by la-
paroscopy. In this case, the approach can be either transperito-
neal or retroperitoneal. On the right side, the liver may make
dissection difﬁcult in a transperitoneal approach.
A Cochrane review comparing open surgery (different ap-
proaches) to laparoscopy (different approaches) for harvesting
living donor kidneys has been published in 2011 . Six studies
were identiﬁed that randomized 596 live kidney donors to
either laparoscopic donor nephrectomy or open donor ne-
phrectomy arms. All studies were assessed as having low or
unclear risk for selection bias, allocation bias, incomplete
outcome data and selective reporting bias. Four of six studies
had high risk of bias for blinding. As various different combi-
nations of techniques were used in each study, there was sub-
stantial heterogeneity in the results. One to 1.8% of the
laparoscopic approaches had to be converted to open donor ne-
phrectomy. Laparoscopic donor nephrectomy was generally
found to be associated with reduced analgesia use, shorter hos-
pital stay and faster return to normal physical functioning. The
extracted kidney was exposed to longer warm ischaemia periods
(2–17 min) with no associated short-term consequences. Open
donor nephrectomy was associated with shorter duration of
procedure. For those outcomes that could be meta-analysed
there were no signiﬁcant differences between laparoscopic and
open donor nephrectomy with regard to perioperative compli-
cations (RR: 0.87, 95% CI: 0.47–4.59), reoperations (RR: 0.57,
95% CI: 0.09–3.64), early graft loss (RR: 0.31, 95% CI: 0.06–
1.48), DGF (RR: 1.09, 95% CI: 0.52–2.30), acute rejection (RR:
1.41, 95 % CI: 0.87–2.27), ureteral complications (RR: 1.51, 95%
CI 0.69–3.31), kidney function at 1 year (SMD: 0.15, 95% CI:
−0.11 to 0.41) or graft loss at 1 year (RR: 0.76, 95% CI: 0.15–
3.85). The authors conclude that laparoscopic donor nephrect-
omy is associated with less pain compared with open surgery.
However, there are equivalent numbers of complications and
occurrences of perioperative events that require further inter-
vention. Kidneys obtained using laparoscopic versus open
donor nephrectomy procedures were exposed to longer warm
ischaemia periods, although this has not been reported as being
associated with short-term consequences.
How did we translate the evidence into the statement?
Based on this Cochrane review, it can be concluded that laparo-
scopic and open approach to harvesting living donor kidney
have comparable outcomes with regard to donor safety and
graft function [394]. The laparoscopic approach seems to have
some advantage in terms of comfort for the donor. It should
however be stressed that, as for most surgical techniques, local
experience might play an important role. These results are
based on randomized controlled trials performed in centres
with great experience in the laparoscopic approach, by a limited
number of surgeons, which reduces the generalizibility of the
ﬁndings. No health economic analyses have been provided.
None of these randomized controlled trials was truly blinded.
The guideline development group concluded that there was in-
sufﬁcient evidence to recommend either open or laparoscopic
approach as a general rule.
What do the other guidelines state?
KHA-CARI states that recipient outcome is equivalent with
laparoscopic and open nephrectomy for living kidney
donation and that recommendations in regard to donor mor-
tality and morbidity cannot be made based on high quality
evidence [395]. The UK Renal Association and British Trans-
plant Society recommend laparoscopic over minimal invasive
open surgery, and, as ERBP, do not prefer a ﬂank subcostal ap-
proach [28, 62]. The European Association of Urology de-
scribes the possible surgical approaches in more detail [29].
They state that laparoscopic techniques have equal outcomes
to open surgery techniques, but result in shorter recovery and
less post-operative morbidity, although they add the rec-
ommendation that this procedure should only be performed
by surgeons with experience with this technique. They do rec-
ommend using the ﬂank costal approach with retroperitoneal
dissection over the transperitoneal approach.
Suggestions for future research
More large-scale, multi-centre randomized controlled trials
are needed to establish the safety of the laparoscopic approach
when applied in a generalized context, and to better quantify
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CHAPTER 4 . PERIOPERATIVE CARE OF THE
KIDNEY TRANSPLANT RECIPIENT
4.1. What are the indications for an additional haemodialy-
sis session in the recipient immediately before the trans-
plantation procedure?
We recommend not routinely performing a haemo-
dialysis session immediately before the actual transplan-
tation procedure unless there are speciﬁc clinical
indications. (1C)
When additional haemodialysis is performed immedi-
ately before the transplantation procedure, we recommend




In some dialysis centres, a routine haemodialysis session
immediately before the transplantation procedure is carried
out to improve the metabolic status of the patient. However,
this is not routinely done in other centres where dialysis is per-
formed only in case of some clinical indications (hyperkalae-
mia, ﬂuid overload). Performing an additional dialysis before
transplantation may increase CIT and activate inﬂammation.
Ultraﬁltration during pre-transplant dialysis is avoided in
some centres, while some argue for ultraﬁltration to improve
cardiac function before surgery; it is unclear whether dehy-
dration might jeopardize graft perfusion and diuresis in the
perioperative phase.
What did we ﬁnd?
In a small (n = 110) randomized control trial, Kikic et al.
found no inﬂuence of haemodialysis without ultraﬁltration
and using biocompatible membranes versus no haemodialysis
on the risk of DGF, and eGFR at Day 5 in deceased kidney
transplantation. In this study arm, patients with hyperkalae-
mia >5 mmol/L were excluded [396].
In a retrospective cohort, Van Loo et al. found the use of bio-
incompatible dialysis membranes along with the application of
ultraﬁltration to be associated with the risk of DGF [397]. The
negative effect of a haemodialysis session immediately before
transplantation, especially when ultraﬁltration was performed,
on immediate graft function was also pointed out by Schmidt
et al. [398].
How did we translate the evidence into the statement?
There is no evidence for a beneﬁt of performing a haemodialy-
sis session just immediately before transplantation. The logisti-
cal organization of such a dialysis session may result in a delay
in the surgery and hence increase CIT.
There is evidence that ultraﬁltration just prior to transplan-
tation is associated with more DGF after transplantation.
As a consequence, the guideline development group rec-
ommends to perform an additional dialysis session immedi-
ately before the transplantation procedure only when there is a
clear clinical or biochemical indication that cannot be resolved
by conservative measures alone.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
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4.2. Does the use of central venous pressure measurement as
a guidance tool for ﬂuid management in kidney transplant
recipients improve the outcome after transplantation?
We suggest that central venous pressure (CVP) is measured
and corrected in the early post-operative period to prevent
hypovolaemia and DGF. (2D)
Rationale
Why this question?
Assessment of adequate hydration status during ﬁrst hours
and days in kidney transplant patients is important for proper
patient management. Dehydration might cause DGF due to
decreased renal perfusion; on the other hand, ﬂuid overload
might result if ﬂuid loading is done in patients who remain
anuric in the post-operative period. It is not clear whether
measurement of CVP measurement provides additional infor-
mation to guide ﬂuid management on top of clinical assess-
ment of the patient.
What did we ﬁnd?
There is limited evidence in the setting of kidney transplan-
tation on the impact of CVP measurement on graft function in
adults, both on short and long term. Most of the published
trials are retrospective descriptive observations.
Othman et al. showed in a small prospective randomized open
trial in 40-living donor kidney transplant recipients that
hydration with normal saline using CVP >15 mmHg as aim
versus at a continuous rate without CVP monitoring is associ-
ated with earlier onset of diuresis and better ﬁrst day graft
function measured by serum creatinine [399]. It was unclear
whether this manoeuvre was associated with decreased inci-
dence of DGF or better graft survival.
In a retrospective case–control study in deceased donor kidney
transplantation, it was demonstrated that CVP <8 mmHg
measured during transplantation was associated with a 3.5
times higher risk for DGF deﬁned as the need for dialysis in the
ﬁrst week after transplantation [400]. In another retrospective
study, intraoperative hydration aiming at a CVP of 7–9 mmHg
had no effect on early kidney graft function [401]. Ferris et al.
observed that after reperfusion of a transplanted kidney, CVP
decreased irrespective of ﬂuid loading [402]. This CVP drop
was not associated with DGF.
How did we translate the evidence into the statement?
This suggestion is based on low grade evidence. However,
there was general consensus in the guideline development
group that good hydration is crucial to avoid DGF.
As most recipients of a kidney graft do have a central line in
place in the immediate perioperative period, measurement of
CVP can easily be obtained. Under these conditions, using
CVP as for guiding hydration seems to decrease the occur-
rence of DGF. Especially sharp increases in CVP should be
taken as an indicator of potential overhydration, or at least as a
sign that further ﬂuid loading is unlikely to result in improved
cardiac output, and that ﬂuid loading should be avoided
accordingly.
The guideline development group judges that placement of a
central venous line just for the measurement of CVP cannot
be defended however. In the same line of reasoning, the
central venous line should also not be maintained with the
sole aim to measure CVP.
What do the other guidelines state?
No other guideline bodies provide a statement on this
topic.
Suggestions for future research
A randomized controlled trial dealing with hydration ac-
cording to CVP measurement in deceased donor kidney trans-
plantation, and comparing different levels of CVP, or
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4.3. In kidney transplant recipients during the perioperative
period, does the use of intravenous solutions other than
0.9% sodium chloride improve patient and/or graft
outcome?
There is no evidence to prefer one type of solution (crystal-
loids versus colloids, normal saline versus Ringer) for intra-
venous volume management of the recipient during kidney
transplant surgery.
In view of the available data in the literature, and in line
with the ERBP position on prevention of acute kidney
injury, we suggest to be cautious with the use of starches in
the kidney transplant recipient during the perioperative
period, although speciﬁc data in this setting are lacking.
(Ungraded Statement)
We recommend monitoring for metabolic acidosis
when normal saline is used as the only intravenous ﬂuid in
the perioperative and post-operative period. (1B)
Rationale
Why this question?
Patients receiving kidney grafts should be properly hydrated to
allow immediate kidney graft function. Post-operative man-
agement differs in various centres and it is unclear whether
crystalloid or colloid solutions are the ﬁrst choice of volume
replacement.
What did we ﬁnd?
In a small randomized controlled double blind trial, O’Malley
et al. compared normal saline versus lactated Ringer’s solution
for intraoperative intravenous ﬂuid therapy in predominantly
living donor kidney transplantation [403]. The study was pre-
maturely stopped since patients treated with normal saline
experienced signiﬁcantly more acidosis and hyperkalaemia.
There was no difference between the two solutions on post-
operative graft function. Five (19%) patients in the normal
saline group versus none in the lactate Ringer group had pot-
assium concentrations >6 mmol/L (P < 0.05). Eight (31%)
patients in the normal saline group versus none in the Ringer’s
lactate group were treated for metabolic acidosis (P < 0.004).
Another randomized controlled trial compared normal saline,
lactated Ringer’s solution and Plasmalyte at comparable
infusion rates (20–30 mL/kg/h) in 90 living donor kidney
transplant recipients [404]. Normal saline decreased pH
(7.44 ± 0.5 to 7.36 ± 0.05 and base excess from 0.4 ± 3.1 to
−4.3 ± 2.1 mmol/L ), whereas Ringer’s lactate was associated
with increased lactate levels (from 0.48 ± 0.29 to 1.95 ± 0.48
mmol/L). None of the solutions resulted in hyperkalaemia.
Although the best metabolic proﬁle was associated with Plas-
malyte, kidney function at ﬁrst post-operative week was
similar. Comparable results were reported by Khajavi et al.
[405].
How did we translate the evidence into the statement?
There is evidence that maintenance of adequate perfusion
pressure during the perioperative phase is of importance to
avoid DGF. There is no evidence comparing crystalloid versus
colloid solutions during kidney transplantation. In other areas
of medicine, all evidence seems to point towards no advantage
of colloid solutions over colloid solutions in patients thought
to need volume replacement [406, 407]. If anything, high
doses of starches might even be associated with increased mor-
tality and risk for acute kidney injury [407].
The type of crystalloid solution seems to have no impact on
graft outcome; however, the use of normal saline can result in
metabolic acidosis, and associated with that, increase in pot-
assium. These can be corrected by using 1.4% sodium bicar-
bonate when appropriate.
What do the other guidelines state?
KDIGO suggests using isotonic crystalloids rather than
colloids (albumin or starches) as initial management for
expansion of intravascular volume in patients at risk for or
with acute kidney injury. They have no speciﬁc recommen-
dation in the perioperative setting of kidney transplantation
[408].
Suggestions for future research
The effect of 0.9% saline versus buffered solutions as per-
fusion ﬂuid in the perioperative phase in kidney transplant re-
cipients needs further investigations with the setting of a
randomized controlled trial.
The effect of lower molecular weight iso-osmolar starches
when compared with crystalloid solutions in the perioperative
phase in kidney transplant recipients needs further investi-
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4.4. Does the use of dopaminergic agents (dopamine and its
alternatives) improve early post-operative graft function?
We do not recommend the use of ‘renal doses’ of dopamin-
ergic agents in the early post-operative period, since it does
not improve graft function or survival. (1B)
Rationale
Why this question?
Low-dose dopamine (<5 µg/kg/min) and alternative drugs, e.g.
fenoldopam, have been proposed to kidney graft recipients as re-
noprotective agents in the early post-operative period aiming at
improving graft function and survival. Such a beneﬁt would de-
crease the risk of delayed graft function and therefore improve
the long-term graft function and survival.
What did we ﬁnd?
In patients with acute kidney injury in the non-kidney trans-
plant population, there is no good evidence for an effect of the
use of ‘renal dose dopamine’ [409].
In a small (n = 20) randomized controlled trial (RCT) in the
ﬁrst 9 h after clamp release, patients were randomized to receive
low-dose dopamine in the ﬁrst 3 h and from 6 to 9 h versus
only in the period 3–6 h [410]. During low-dose dopamine in-
fusion, urine ﬂow rate, effective renal plasma ﬂow, creatinine
clearance and total urinary sodium excretion were enhanced;
however, no data on DGF, or later graft function were available.
In another largely underpowered RCT (n = 18), McCune et al.
did not ﬁnd a difference in serum creatinine at 48 h and at 30
days between patients treated with fenoldopam or placebo
[411].
Three small randomized controlled trials showed better short-
term graft function and reduced risk of DGF with low-dose
dopamine in comparison with no dopamine, but all were at
high risk of bias (multiple testing, potentially selective
outcome reporting, patient selection, immunosuppression era,
adjustment from confounding factors, limited information
due to congress abstract source, number of patients) [412–
414]. Another slightly larger RCT at moderate risk of bias
found no evidence for a clear effect of treatment on short-term
outcomes [415].
When it comes to outcomes at 3 months to 1 year after trans-
plantation, four small retrospective cohort studies also failed
to show evidence suggesting beneﬁt for patients treated with
low-dose dopamine, both in terms of patient and graft [416–
419].
How did we translate the evidence into the statement?
There is no evidence to support that low-dose dopamine can
improve graft outcome in terms of relevant outcomes as DGF,
or serum creatinine levels in the mid-long and long term. The
use of low-dose dopamine might induce arrhythmias. As such,
the guideline development group judged that the use of low-
dose dopamine could not be recommended. The existing evi-
dence does not support that alternative dopamine agonists,
such as fenoldopam, have a more positive proﬁle. As a conse-
quence, also the use of these agents cannot be recommended.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
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4.5. Should we use prophylactic antithrombotic agents
during the perioperative period?
We do not recommend routinely using low-molecular-
weight heparin, unfractionated heparin or aspirin before
transplantation to prevent graft thrombosis. (1B)
Rationale
Why this question?
Patients treated with dialysis might be at higher risk for throm-
boembolic events, especially arterio-venous ﬁstula thrombosis,
deep vein thrombosis and embolism for reasons that are
poorly understood. In some of those patients graft vein throm-
bosis or other thromboembolic events may occur after kidney
transplantation. Prophylactic use of antithrombotic agents
potentially reduces that risk at the cost of increased bleeding in
the immediate post-operative period, with the potential need
for re-intervention and damage to the transplanted organ.
What did we ﬁnd?
In a randomized trial in 75 living donor kidney transplant reci-
pients, there was no event of thromboembolism in either the
treatment arms (low-molecular-weight heparin or unfractio-
nated heparin) or the placebo arm during the ﬁrst week after
transplantation, while there was a small comparable risk for
bleeding complications in both arms [420].
In a small moderate quality randomized control trial in de-
ceased donor kidney transplantation, Horvath et al. evaluated
pre-operative injection of 2500 units of heparin or placebo fol-
lowed by 17 days of therapy [421]. Three-month graft survival
and the number of thrombotic events were similar in both
arms. Bleeding events were numerically more frequent in the
intervention arm but low event numbers made conﬁdence in-
tervals wide and results not statistically signiﬁcant (RR: 11.00,
95% CI: 0.65–185).
Lundin et al. conducted a retrospective study in 120 kidney
transplant recipients [422]. Fifty-six patients received prophy-
laxis with low-molecular-weight heparin, two patients received
low-dose unfractionated heparin and the remaining patients re-
ceived no prophylaxis. Graft thrombosis occurred in a single case
in the control arm. Bleeding events were similar in both arms,
and although there were numerically more graft nephrectomies
in the control arm (4/64 control versus 0/56), the result was not
statistically signiﬁcant and reasons for this observation were not
reported. There was a slightly higher incidence of ultrasonogra-
phically diagnosed lymphoceles in the interventional arm (RR:
2.11, 95% CI: 1.19–3.74), but the number of lymphoceles
needing intervention was similar (10/56 versus 11/64).
We found one retrospective cohort study (n = 200) in which
low-dose heparin given just before vascular clamping was
compared with no prophylaxis [423]. Although both the
number of patients experiencing graft thrombosis and the
number needing blood transfusions were numerically higher
in the control group, results were not statistically signiﬁcant
and conﬁdence intervals wide.
We found one study in which 105 patients treated with aspirin
during the ﬁrst 3 months along with low-molecular-weight
heparin for ﬁrst 5 days after transplantation were compared
with 121 historical controls [424]. They found numerically
fewer events of graft thrombosis and biopsy-proven chronic al-
lograft nephropathy at 1 year. None of these results was adjusted
for confounding or statistically signiﬁcant and conﬁdence inter-
vals were very wide.
In another retrospective cohort study, Nagra et al. found
similar numbers of graft thrombosis leading to graft loss after
heparin prophylaxis compared with no prophylactic anticoa-
gulation. Among the 254 patients, there was one bleeding inci-
dent leading to graft loss [425].
Finally, we found two retrospective cohort studies comparing
low-dose aspirin with no prophylaxis during the ﬁrst moth
after transplantation. Both found fewer cases of graft thrombo-
sis but used a historical control group and did not attempt ad-
justment for potential confounding in their analysis [426,
427].
How did we translate the evidence into the statement?
There is no consistent and convincing evidence for routine
antithrombotic therapy by unfractionated or low-molecular-
weight heparin. There is no study dealing with low dose heparin
or low-molecular-weight heparin prophylaxis in patients with
obvious risk of thrombosis such as genetic mutation of factor V
Leiden, prothrombin mutation or those already on anticoagula-
tion therapy. As these patients do have an indication for antic-
oagulation anyway, and as there is no convincing consistent
evidence for an increased bleeding risk, we suggest such patients
to receive low-molecular-weight heparin prophylaxis for 4
weeks as recommended by the Haematological Society. (2B)
Aspirin with the sole purpose of preventing renal vein
thrombosis should not be started in patients who are not
already on the treatment for other indications. In patients who
have an indication for chronic antiplatelet drugs, aspirin
should not be stopped, as the pharmacodynamic action on
platelet activity lasts >7 days.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
We need an adequately powered randomized controlled
study to clarify the risks and beneﬁts of prophylactic treatment
with low-molecular-weight heparin in the perioperative period
in kidney transplantation.
Insufﬁcient evidence is reported on safety and bleeding risk
of kidney biopsy in kidney transplant patients under anti-
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4.6. In kidney transplant recipients, what are the effects of
using a JJ stent at the time of operation on outcomes?
We recommend prophylactic JJ stent placement as a routine
surgical practice in adult kidney transplantation. (1B)
We suggest that if a JJ stent is in place, cotrimoxazole is
given as antibiotic prophylaxis. (2D)




Placement of a prophylactic ureteric stent is mostly done to
protect the connection of the donor ureter with the bladder of
the recipient, to avoid urinary leakage in the post-operative
phase and to avoid strictures. However, placement of a JJ stent
enhances the risk of infection and reﬂux. In addition, the
removal of the JJ stent in a second stage can pose logistical
problems and cause inconvenience and discomfort for the
recipient.
What did we ﬁnd?
A recent Cochrane review on this topic included seven random-
ized controlled trials (total 1154 patients) of low or moderate
quality [428]. In this systematic review, the incidence of major
urological complications was signiﬁcantly reduced (RR: 0.24,
95% CI: 0.07–0.77, P = 0.02, NNT 13) in patients who had a
prophylactic stent in place. However, the authors pointed out
that the result was dependent on whether the same surgeon per-
formed or attended the operations, so there might be a de-
creased effect in surgeons with high experience. However, also
in the subgroup where all interventions were done by the same
surgeon, a beneﬁcial effect of prophylactic stenting was ob-
served (RR: 0.39, 95% CI: 0.08–1.86, NNT = 30). The incidence
of major urological complications in the non-stented group dif-
fered widely between the different studies (0–17%), whereas this
was far less in the stented group (0–4%). Two patients lost their
grafts to infective urinary tract complications in the stented
group. Urinary tract infections were more common in stented
versus not stented patients (RR: 1.49, 95% CI: 1.04–2.15), unless
the patients were prescribed co-trimoxazole 480 mg/day. In that
case, the incidence was equivalent (RR: 0.97, 95% CI: 0.71–
1.33).
In a recent retrospective single-centre study cohort (n = 961,
32% of whom did not receive a stent), ureteral complication
rate was 1.9% in stent versus 5.8% in the no-stent group
(P = 0.007) [429]. Urinary tract infection rate was 14% with
stent versus 8% without stent (P = 0.003). Stent use was inde-
pendently associated with reduction in ureteral complications
(incidence rate ratio 0.40, 95% CI: 0.17–0.96) and an increase
in risk for urinary tract infection (RR: 1.79, 95% CI: 1.18–
2.74). Stent protective effect was primarily related to reduction
in stricture risk (RR: 0.23, 95% CI: 0.05–0.99). Stents were re-
ported in this study to be associated with a decrease in ureteral
complications in deceased donor recipients (RR: 0.34, 95% CI:
0.13–0.88), but not living donors (RR: 1.24, 95% CI: 0.15–
10.2), but only 10% of living donation recipients (23/263) did
actually receive a stent, so there is a high risk for bias by indi-
cation and lack of power for this subgroup analysis.
There is no evidence for such a beneﬁt in children and there is
no consensus among paediatric transplant surgeons for using
prophylactic ureteral stenting.
How did we translate the evidence into the statement?
In view of the published evidence, prophylactic placement of a
stent should be recommended. In experienced hands, the ex-
pected beneﬁts are lower, but still present.
Some members of the guideline development group judged
that in experienced hands, and when logistical circumstances
to remove the stent in a second stage are difﬁcult, performing
a transplant without placement of a stent can be acceptable.
The major complication of stenting is urinary tract infection.
As the risk seems to be similar for those who do not receive a
stent when patients are given cotrimoxazole, we suggest cotri-
moxazole is given as antibiotic prophylaxis.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
It is deemed unlikely that further RCTs will change the evi-
dence we have so far. However, RCTs on the most optimal
timing of removal of the stent are needed. Also studies to clarify
under which conditions and/or in which type of patients no JJ
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4.7. What is the optimal post-operative time for removal of the
indwelling bladder catheter in kidney transplant recipients?
We suggest removing the urinary bladder catheter as soon
as possible after transplantation, balancing the risk of
urinary leak against that of urinary tract infection. (2D)
We recommend monitoring adverse event rates (urinary
tract infection, urinary leakage) in each centre, to inform




An indwelling bladder catheter can protect the fresh suture of
the ureter on the bladder and reduce major urological compli-
cations. On the other hand, it can be an additional source of
infection, prolonging the initial hospitalization due to urinary
tract infection [430]. There is still a controversy as to the most
optimal post-operative day to remove the indwelling catheter
[431].
What did we ﬁnd?
We did not ﬁnd any randomized trial on this topic.
A single-centre retrospective analysis compared patients in
whom the bladder catheter was removed on the second post-
operative day (n = 66) to those in whom it was removed later
(n =75) [432]. All patients had also a ureteral JJ stent. The
median length of stay was 3 days in group A compared with 5
days in group B (P = 0.001). Urinary retention requiring
reinsertion of the urethral catheter occurred once in group A
(1.5%) and twice in group B (2.6%). There were no urine leaks
in neither of the groups. Readmission within 30 days of trans-
plantation was signiﬁcantly associated with DGF (P = 0.016)
and longer post-transplant length of stay (P = 0.001), but not
with the post-operative day of urethral catheter removal (P =
0.14). By its design this study was highly prone to bias by indi-
cation however. This risk of bias is also substantial in two other
reports demonstrating a similar (2.6 ± 1.4 versus 2.4 ± 1.1 days
in those with versus without urinary tract infection in the ﬁrst
months post-transplantation) [431] and a longer bladder cathe-
terization (6.5 ± 5.5 versus 5.2 ± 2.9 days in those with versus
without urinary tract infection in the ﬁrst year after transplan-
tation) in kidney recipients, respectively [433].
In a small (n = 57) observational single-centre cohort, the
odds ratio for developing a urinary tract infection while having
a bladder catheter in place for >3 days was 1.48 (95% CI: 0.35–
6.19) [434]. The analysis was, however, not adjusted for poten-
tial confounders. Finally, we found one retrospective cohort
study comparing catheter removal between the second and
third day with leaving the bladder catheter in place for >1
week. On average, the risk for developing urinary tract infec-
tion was twice as large for patients in the early catheter
removal group. Both groups had, however, received antibiotic
prophylaxis and the analysis was not corrected for possible
confounding [435].
How did we translate the evidence into the statement?
The evidence came only from a few retrospective studies, with
poor design and probable bias. Nevertheless, early catheter
removal (2 days) was associated with shorter length of the hos-
pital stay, and less risk of infection. There were no numbers to
assess the potential inﬂuence on urological complications of
early removal of the bladder catheter.
As such, the guideline development group judged that pros and
cons of removal of the bladder catheter should be weighed on an
individual patient basis daily from the second post-operative day
onwards. As information, even observational, is grossly lacking,
centres should document their own experience to help steering
the decision process. It is important that this is done by individ-
ual centres, as the ideal day might be dependent upon factors
related to local procedures and techniques.
What do the other guidelines state?
No other guideline body provides a statement on this topic.
Suggestions for future research
A randomized clinical trial on the adverse event rates
(urinary tract infection, urinary leakage) in patients in whom
the bladder catheter is removed early versus later in the post-
operative period is highly needed.
Transplant centres should be stimulated to register their
own complication rates (infections and urological compli-
cations), and adapt timing of removal of the indwelling
bladder catheter accordingly.
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